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Abstract
Building a sustainable bioeconomy requires strategic alliances, intellectual property, 
funding and talent. The research focus of this empirical study was to assess Malaysian 
biotechnology companies regarding their opinions on priorities and capabilities necessary 
to establish a thriving bioeconomy. The research questions that form the basis of this 
paper explore the extent to which initial factor endowments affect the trajectory of 
biotechnology industry development and how Malaysia should prioritise, mobilise and 
coordinate resources to build a bioeconomy. A mixed methods approach using qualitative 
interviews and case studies, as well as a quantitative survey, indicated that respondents 
advocated a resource-based-view in terms of resource allocation and agglomeration 
towards building Malaysia’s bioecnomy. That is, there was strong support to leverage 
Malaysia’s existing capabilities in agriculture and biofuels to derive value-added products 
towards gaining leadership positions in these respective biotechnology sectors globally. 
Access to funding and talent emerged as the highest priority capabilities necessary for 
commercialising discoveries, conducting research and development and accelerating 
innovation. Respondents perceived the government as having a ‘very important’ role in 
building and accelerating the Malaysian biotechnology industry. The gap between 
required capabilities and strategic priorities provides a framework within which the 
government may play a central role in coordinate, accelerating and resourcing Malaysia’s 
nascent bioeconomy. 
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1Introduction
Biotechnology, information technology, and the globalisation of capital markets are 
entrepreneurial mega-force multipliers for future economic development and 
productivity. The biotechnology industry has similarities to the innovation and diffusion 
patterns of the information technology era. To date, the biotechnology industry and 
market has evolved from a technologically-advanced and highly specialised area to an 
increasingly common and enabling technology with vast commercial applications and 
entrepreneurial opportunities throughout all sectors of the global economy.  This can be 
attributed to advancements in biologic insights, decreasing costs of new discoveries and 
widespread availability of research tools. Even though the biotechnology industry can be 
termed as an ‘emerging’ after only three decades of scientific and entrepreneurial resolve, 
there is great potential in addressing significant challenges in developed and developing 
nations like healthcare, security, substitute or renewable energy sources, environment 
rehabilitation and agricultural productivity (BIO,2007; Burrill 2007; CHI, 2006; Ernst & 
Young, 2008).
Public and private stakeholders wanting to create and increase bioeconomy 
competitiveness and reduce the effect of distance face enabling trends such as increasing 
numbers of science graduates, accelerating pace of scientific advancement leading to 
greater public-private sector collaboration enabled by globalisation, democratising forces 
of the internet and the relentless competitive pressure to innovate (Furman et al, 2002; 
Iammarino and McCann, 2006; Casper, 2007). Earlier studies on multinational 
biotechnology leaders, has shown that the number of strategic alliances has twice the 
performance impact compared to geographic proximity to partners (Ahn and Meeks, 
2007; Ahn et al, 2008). Even though dyads or formal networks of related parties such as 
public sector research and private investment capital are critical, formation of regional 
capabilities have depended on local context (Stuart and Sorenson, 2003; Andersson et al, 
2004; Casper, 2007).
2Global trends and with Malaysia’s biotechnology industry in its early stages of 
development; identification of key sector priorities and developing capabilities required 
to achieve global competitiveness is crucial. This study examines the development 
process of building a sustainable bioeconomy by analysing the perceptions and attitudes 
of industry participants concerning the key attributes and priorities in Malaysia. We 
explored growth patterns, industry platforms and networks; and enabling factors that 
support entrepreneurial activity, innovation, productivity, sustainability and research 
development. Questions explored include: Do initial factor endowments affect the 
trajectory of a biotechnology industry? How should Malaysia prioritise, mobilise and 
coordinate resources to build a sustainable bioeconomy?
Case studies, confidential interviews and an online-survey were conducted to collect data 
from Malaysian biotechnology companies that are part of the Bionexus Network. This 
network is an exclusive group of promising companies that have been targeted by 
Biotech Corporation Malaysia as potential future industry leaders. Multiple case studies 
were done to capture a rich set of secondary data and an online survey of Malaysia’s 
Bionexus network participants to provide insights and directions on biotech sector 
priorities, capabilities and competitiveness. A summary of conclusions and 
recommendations for policy makers, practitioners and academics was considered.
3Literature Review
Global Biotech Industry
Biotechnology is the process of applying “biological knowledge and techniques to 
develop products and services…[with] any technique that uses living organisms to make 
[or] modify products, improve plants or animals, or develop micro-organisms for a 
specific use” (BIO, 2006; Goetz and Morgan, 1995). The biotechnology industry consists 
of key sectors: biofuels, molecular diagnostics, agriculture and nutraceuticals; and 
biopharmaceuticals. 
Biofuels
Biofuels are a type of renewable resource that is derived from organic plant matter or 
animal origin, widely-distributed compared to fossil and nuclear resources and has the 
Literature Review
Research Question
Research & 
Procedure
Conclusion
 Defining core capabilities for building a sustainable 
bioeconomy
 Developing concepts for biotechnology clusters
 Do initial factor endowments affect the trajectory of a biotechnology 
industry?
 How should Malaysia prioritise, mobilise and coordinate scarce 
resources to build a sustainable bioeconomy?
Multiple Case-Studies
Confidential Personal Interviews
Survey/Questionnaire
 Leverage on existing advantages in agricultures, food and biofuels to 
build leadership position in respective biotechnology sectors
 The gap between desired and current capabilities provide a framework 
of improvement which the government has a central role of 
coordinating, resourcing and accelerating growth and resources of the 
nascent Malaysia bioeconomy
4potential to provide energy (Demirbas, 2007; Frost & Sullivan 2007). Currently biofuels 
are blended with ethanol and diesel to power petrol and diesel-driven engines 
respectively. Biofuels have received increased media and scientific attention after initial 
research had identified a decrease in carbon dioxide emissions when used as fuel and 
possible links to decrease overall greenhouse gas emissions.  Biofuels have also been 
linked to contribute positive social and economic benefits to countries like Germany, 
Brazil, United States and the United Kingdom (Frost & Sullivan, 2007a; Demirbas, 
2006). The biofuels industry has developed rapidly in regions like the Asia-Pacific 
especially in developing countries like India and China. To date, China and India are 
ranked top-consumers globally in terms of energy needs and consumption. Their 
dependence on scarce fossil fuels and need for more sources of fuel, mirror developed 
countries that have invested in biofuel research and production facilities. Nevertheless, 
this demand has opened up potential export markets for biofuel producers. From 2000-
2007, statistics by the International Energy Agency (IEA) has shown a steady increase in 
biofuel production from 2 billion gallons to 17 billion gallons (1 gallon = 3.785 litres) 
(Coyle, 2007). The United States, Brazil, China and India are the top producers of 
bioethanol, with the United States producing approximately 16.2 billion litres of ethanol 
in 2005 (Frost & Sullivan, 2007b; Coyle, 2007; Burrill 2007). 
An illustrative example is Neste Oil, established since 1948, a Finland-based oil-refining 
and renewable diesel company with an annual turnover of EURO$12.103 billion 
(~US$16.1 billion) and more than 4,800 employees (NesteOil, 2009). Neste Oil has 
established refining facilities from Edmonton, Canada to St. Petersburg, Russia and 
Bahrain to Singapore. Key products manufactured are petroleum, oil-component 
lubricants and solvents. Prior to 2005, Neste Oil mainly refines crude-oil for export and 
sale and producing other petroleum-related products. In 2005 Neste Oil started research 
and development (R&D) on renewable fuels and establishing biodiesel plants in Finland 
which is available for export since 2007. Meanwhile Neste Oil has commenced building 
biodiesel plants in Singapore by 2010 and Rotterdam in 2011 in order to increase 
production capacity and be the world’s leading biodiesel manufacturer. This can be seen 
as a strategic move by Neste Oil since both ports have a combined processed handling of 
5over 800-million tons of cargo-tonnage and are ranked as the top 3 busiest sea-ports in 
the world in 2006. Establishing a biodiesel plant in areas which have heavy shipping-
traffic gives Neste Oil an advantage of being closer to potential target markets like 
refuelling or selling biodiesel to shipping containers and tankers. Currently Neste Oil’s 
biodiesel is manufactured from vegetable oils and animal fats. Neste Oil has begun
initiatives on R&D towards cultivation of existing crops that do not compete with food 
production nor has no food-value. 
The Kyoto Protocol was ratified in 1997 and countries that were signatories are 
committed to reducing greenhouse gas emissions by 2012. This is a significant market 
driver for the biofuels industry as participating governments are likely to have increased 
research incentives to biotechnology companies and research institutes and pushed forth 
policies and legislations. The market drivers for biofuels appear to be volatile oil prices, 
compatibility with existing fuel infrastructures, production facilities and capabilities and 
availability of biomass or feedstock. Market restraints are capital investments for 
production facilities, skilled scientist and workers and government incentive programs.
Biopharmaceuticals
Biopharmaceuticals are classified as drugs and drug therapies which are produced 
through the use of living cells that treat, control and cure medical conditions such as 
AIDs, cancers and others (Gurau, 2004; Gwyne, 2004; Burrill 2008). Biopharmaceuticals 
represent the largest area of investment and revenue, with over $70 billion in sales in 
2007. Since the approval of the first biotechnology drug by US FDA (Food and Drug 
Administration) in 1982, the total number of drugs has increased to 254 with 385 
applications. Furthermore with another 300 drugs under clinical developments, targeting 
over 200 diseases, this represents over $20 billion in annual research and development. 
Consequently the pharmaceutical industry has emerged as a significant source of new 
venture creation with over 700 public-listed firms reporting double-digit growth in North 
America, Europe and Asia-Pacific. 
6An emerging trend in biopharmaceuticals is human therapeutics. This has been the largest 
segment of the biopharmaceuticals industry, with technology spill-over effects into high-
growth markets like molecular diagnostics ($3.5 billion), nutraceuticals and functional 
foods ($50 billion), environment ($30 billion), biosecurity ($7 billion) and biofuels ($6 
billion) (BIO, 2007; Burrill, 2007; Kalorama, 2006). 
An illustrative example is Amgen, established in 1980, US-based Fortune 500 human 
therapeutics company situated in Thousand Oaks, California, with more than 20,000 
employees and annual turnover of US$14.3 billion . With over 25 years experience in 
biopharmaceuticals, Amgen uses DNA and molecular biology to pioneer new drug 
developments aimed at treating rheumatoid arthritis, anaemia, cancers and kidney 
diseases. Global estimates suggest that close to 5 million people world-wide are long-
term chronic sufferers of rheumatoid arthritis with 1.3 million people in the United 
States. In New Zealand,  rheumatoid arthritis occurs in one to two out of a 100 people 
and women are three time more susceptible than men; which puts the overall figure at 
44,000 sufferers (ArthritisNZ, 2009). 
Symptoms may range from painful or stiff joints to more severe cases like tendon 
inflammation and swelling of joints. This disease occurs at any age and is not hereditary. 
It is also long-term, chronic, and incurable and might recur any time. Prior to medication, 
exercise and rest were the main methods of managing this disease. However due to the 
recurring nature and inflammatory symptoms, medication has emerged to be the main 
source of managing this disease. Through intensive R&D with a team of chemists and 
scientists, Amgen pioneered ENBREL, a drug which lowers the amount of tumour 
necrosis factor (TNF) created by the immune system. Research in rheumatoid arthritis 
pin-pointed the immune system for over-producing amounts of TNF which causes this 
disease. Therefore ENBREL should reduce the amount of TNF in the body to normal 
levels. At this current point in time, there is no cure for rheumatoid arthritis. However 
biopharmaceutical companies have been experimenting with ‘regenerative tissues and 
medicines’ as a possible cure. 
7Nutraceuticals
Nutraceuticals was coined in 1989 by Stephen Defelice as a food or part of a food that 
contains or provides nutritional value beyond normal levels and is able to offer medical 
and health benefits (DeFelice, 1995; Andlauer & Furst, 2002; Belem, 1999; Ekta, 2003). 
Nutraceuticals are the fastest-growing segment in the food industry with estimates of the 
market being between US$30-60 billion (Andlauer & Furst, 2002; Belem, 1999; Hard, 
2000; Thompson & Moughan, 2008). 
The nutraceutical interest started in the early 1980s when the actual or potential benefits 
of calcium, fiber and fish oil commonly found in food were supported by clinical studies 
in distinguished medical journals (DeFelice, 1995). The popularity for nutraceuticals can 
be attributed to two reasons: one being the growing awareness of the importance of good 
health and secondly the lack of viable alternatives. 
In affluent nations, there are a variety of health issues that are currently affecting the 
people. Obesity, cancers, and a lack of exercise are some issues that affect these people. 
Nutritionists have advised the benefits of a balanced diet with adequate amounts of 
protein, fibre and exercise. However these dietary reference values do not take into 
account the diverse types of consumers who are impacted by different health issues at 
different stages in their lives by virtue of differing circumstances. Though the 
consumption of certain foods may improve health and well-being, however the idea of 
food proving more than just the basic nutritional values is apparently not new as in 
400BC, Hippocrates was reported to have said ‘Let food be your medicine and medicine 
be your food’ (Thompson & Moughan, 2008). 
Currently companies involved in investigating and developing nutraceutical products 
belong mainly to food technology companies at 55% and pharmaceutical companies at 
35%, with a steadily growing amount of strategic alliances in place between these two 
types of competitors (Belem, 1999). Products in nutraceuticals are also increasingly 
converging with other foods as a result of functional ingredients being added to more 
8products in order to satisfy consumers’ different needs in one transaction (DeFelice, 
1995; Ekta, 2003; Thompson & Moughan, 2008). 
An illustrative example is Kraft Foods, established in 1903, a US-based Fortune 500 
company with more than 103,000 employees and annual sales of US$37.2 billion (Kraft, 
2009). Kraft Foods is a heavily-diversified food and beverage company which have 
added a line of healthy-alternative food-products. Termed as “Health & Wellness”, this 
range of healthy-alternatives are pushed-forth by Kraft to target the health-conscious 
consumers. By promoting healthy living and eating-choices, Kraft advertises their 
products to help consumers manage their weight, and add fibre or calcium into their diet. 
The driver for this health-range is due to the company’s vision and strategy of making 
their products more contemporary and relevant through identifying key consumer-trends 
and being able to cater to their ever-changing needs. Kraft has established strategic 
alliances with various pharmaceutical companies to cooperate on food and nutrition R&D 
and have engaged an international panel of advisors and scientists to head a council 
which monitors their functional health food-products and nutritional-values. The 
scientists come from Malaysia, United States and United Kingdom. With an international 
team of advisors, Kraft is able to package, label and include relevant nutritional and 
dietary information for consumers world-wide. An example is the “100-Calorie Packs” 
commonly-sold in the United States and Canada, which caters to health-conscious 
consumers who want to snack but stay on track with their healthy and balanced eating 
routine. To date, this product-category has grown into a US$100 million brand with new 
products routinely added.
Agriculture
Agriculture biotech utilises biotechnology to supplement traditional methods of 
agriculture to increase yields per land ratio and disease-resistant crops. A widely-
accepted definition is the utilisation of biotechnology to understand and manipulate the 
genetic make-up of organisms for use in production or processing of agriculture products 
9(GreenFacts, 2004). To date, the common applications of agriculture biotechnology 
include crops, livestock, forestry and fisheries (Frost & Sullivan, 2004). There are two 
major segments in the agriculture-biotech sector. One being the genetically-modified 
(GM) crop market and the other is the ‘value-added agriculture’ which involves the 
agricultural production of proteins that includes pharmaceutical and industrial 
applications in crops (Frost & Sullivan, 2003). Biopharmaceuticals have teamed up with 
agriculture-biotech companies to cultivate and produce crops with pharmaceutical 
properties to treat diseases.
For agriculture, GM crops have increased in popularity and the global market is estimated 
at US$7.5 billion (Frost & Sullivan, 2003). The common GM crops are cotton, corn, rice 
and soybean. These crops are often genetically-modified to increase disease-resistance, 
enhanced taste, nutritional values and economies of scales. Other than cotton, the rest are 
important as they form part of staple-diets of most people around the world.
According to population estimates by the United Nations, the total global population will 
reach 9.3 billion people in year 2020 and food production needs to be doubled to feed 
everyone. Difficulties like reduction of arable land for housing and increased competition 
for water resources are some of the factors affecting agriculture and food production. 
Thus there is a current pressing need to increase agriculture productivity within existing 
arable lands, increase crop-yields and increase food production methods. 
To illustrate an example, Monsanto, established in 1901, a US-based Fortune 500 
agriculture company with more than 22,000 employees and annual sales of US$11.4 
billion (Monsanto, 2009). Monsanto produces seeds for large-acre crops like corn, cotton, 
soybeans, wheat and canola, and small-acre crops like vegetables. Their seeds are 
biotechnologically-engineered to increase crop-yields, disease-resistant crops to reduce 
usage of pesticides and increased nutritional values. Monsanto also offers crop protection 
products like herbicides to increase agricultural productivity. Through extensive R&D, 
Monsanto has formulated their herbicides to reduce or not impact crops which are 
sprayed on and contain no harmful substances that might kill other forms of wildlife or 
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pollute nearby streams or rivers through surface-runoffs. For 2009, Monsanto has 
included R&D projects into developing drough-tolerant corn crops for drought-prone and 
water-scarce areas and countries; higher-yielding soybeans and second-generation 
herbicides.
Medical Diagnostics and Devices
Medical diagnostics, sensors and biosensors are medical equipment built with the purpose 
of detecting diseases, illnesses and other bodily fluids. A formal definition of such 
technology dictates a compact analytical device incorporated with biological sensitive 
material that will form a biochemical reaction after contact with body fluid (Owen, 1985; 
Albinson, 1987; Smith, 2005). This, in most cases, is a colour band to indicate positive or 
negative results. 
To date, the medical diagnostics industry is estimated at least US$ 15-29 billion and with 
annual growth rates of 10-15% (Smith, 2005; Batchelder & Miller, 2006). This 
encompasses clinical chemistry, advanced instrumentation and medical imaging like 
Magnetic Resonance Imaging (MRI). The diagnostics market is still dominated by well-
established companies like Roche Diagnostics, Abbott Diagnostics, Johnson & Johnson 
Diagnostics and Bayer Diagnostics which amount to majority of total revenue generated 
(Baker, 2006). Advancements and merging of different technologies has created a wide 
variety of device (Rowley, 2002; Burrill 2008). 
Diagnostic kits are increasingly popular as these products have the potential to reduce 
lengthy clinical trails in which a drug company has to conduct experiments or trials to 
ensure the product is safe for human consumption. An emerging feature of this industry is 
due to the Baby Boomers Generation, as they are knowledgeable about healthcare and 
treatment options and willing to monitor their health. Therefore life-science companies 
are responding with new product offerings that are less invasive, painless, convenient and 
increasingly affordable (Newman et al, 2001; Eselius et al, 2008). 
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An illustrative example of such merging technologies is Boston Scientific, a US-based 
Fortune 500 medical diagnostics company with more than 25 years experience is the 
world’s largest company dedicated to less-invasive medical devices. The company 
employs more than 25,000 employees and distributes more than 13,000 products in over 
45 countries with an annual sales turnover of US$8.1 billion (Boston Scientific, 2009). 
Boston Scientific has an innovative product, LATITUDE 360° of care – Remote Patient 
Management System. This is a home-monitoring machine/system offered to cardiac 
device patients and families. It allows cardiac patients with implanted cardiac devices to 
receive medical consultation and check-ups at home and reduce clinic visits. The devices 
collect information and transmit data to the monitoring system which utilises a standard 
phone line to transmit data to a secure website hosted by Boston Scientific. The 
monitoring doctor is able to make diagnosis, dispense medication and monitor patient-
progress. The implanted cardiac devices monitor abnormal heart rhythms and heart 
failures. Any major heart failure triggers the alarm on the monitoring system which 
prompts the monitoring doctor to take medical action and rescue the patient from home. 
Patients are also advised to conduct their own medical check-ups twice a day, each 
lasting 2-3 minutes.
Biotechnology firms operate globally from inception due to their reliance on intellectual 
property (IP) exclusivity. Strategic alliances with other research institutes and smaller 
biotech companies offer another way of organising and controlling a firm’s value chain 
and preferred compared to vertical integration (Trigeorgis, 1996; McGrath, 1997; 
Vassolo et al, 2004). Barriers to entry have rapidly decreased and innovation is becoming 
increasingly ‘balkanised’ into smaller firms and research institutes therefore business 
models in biotech are constantly evolving and appear similar to the process of project 
management in movie production in contrast to their historic pharmaceutical parentage. 
Moreover globalisation and advance information systems networks enhance the 
possibility of virtual operations and teams; and accessibility to the biotech ecosystem 
open to contract manufacturers for process developments, research organisations with 
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unique testing capabilities, patent lawyers, venture capitalists, and others who enable 
start-up formation and development (Burrill, 2007; Pisano, 2006). 
The next section will analyse the concept of biotechnology clusters within the context of 
industry development trends and capacity building.
Building Biotech industry Clusters
Clusters are concentrations of competing and cooperating companies, suppliers, service 
providers and associated institutions (Rinaldi, 2006). This is a concept based on the 
definition by Michael Porter (1990) Competitive Advantage of Nations. According to 
Porter’s definition, clusters are geographic concentrations of interrelated individuals, 
firms and institutions which compete and collaborate by accumulating knowledge and 
intellectual capital (Ahn et al., 2009). Clusters can be a concentration of any industry and 
are not limited to only the biotechnology sector. The aim of establishing clusters is to 
enhance levels of productivity and innovation through increased proximity of players. 
This proximity reduces institutional boundaries and allows knowledge to flow freely. One 
example is the development of Euro BioCluster, a meta-cluster which is a formation of 
participating biotech clusters from Germany to Spain to form a ‘super’-cluster (Rinaldi, 
2006). Established since 1996, it houses 400 biotechnology companies, more than 150 
academic and research institutions and 40% of the world’s pharmaceutical companies 
have established a presence in the BioCluster (Byrum, 2004).
The economies of agglomeration build on Porter’s cluster theory by suggesting a firm’s 
performance is influenced by the presence of other firms within the boundaries. These 
advantages are attributed to knowledge, skilled labour; innovation and input spill-over 
(Ahn, Meeks, Ross, Dalziel & Bednarek, 2008).
Cluster approaches may be viewed in the theoretical context of the Resource-Based View 
(RBV). According to Barney (1991), the definition of RBV suggests that rare, valuable 
firm resources and capabilities that are hard to duplicate provide a firm with competitive 
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advantage (Hart, 1995). Such resources may range from a variety of categories from 
financial, organisational, and physical; and the competitive advantages derived are based 
on the value and rareness. 
The underlying assumption of the RBV perspective is that resources and capabilities are 
heterogeneous across firms (Peteraf, 1992). Therefore when firms are endowed with such 
resources, they are able to produce more economically and better satisfy customer wants. 
Thus if a competing firm is unable to imitate, create or develop the same resources, the 
time-lag in between is classified as a source of competitive advantage for the firm which 
is able to acquire the set of resources. However the premise of sustained competitive 
advantage cease to exist once there are equivalent substitutes in a competitive situation. 
(Barney, 2001) Thus to establish a sustainable competitive advantage, a firm needs to 
evaluate, find and protect that resource; either physical or intangible through intellectual 
property protection, trade secrets or trademarks. 
In the strategic management field of study, the match between internal and external 
circumstances should produce competitive advantages (Hart, 1995). Thus competitive 
advantage will depend on the match between organisational capabilities (internal) and 
environmental (environmental) circumstances. Makadok (2001) states that capabilities 
are a type of resource, which is organisation-specific, unique and an inherent quality 
which is designed to combine all the other resources possessed by the firm and produce 
economic return. Thus capabilities in Makadok’s view is firm specific, non-transferable 
and can be seen as an important quality to harness all the other resources to achieve an 
economic rate of return. 
Makadok views capabilities as being acquired over time and not purchased, but they must 
be built. According to Makadok, this is termed as “capabilities building”. In order to 
build capabilities, some essential drivers necessary to be developed and nurtured might 
be knowledge, skills and behaviours. Utilising cluster approaches can be a source of 
“capabilities building”, since companies in the cluster may cooperate together in strategic 
alliances and decrease any potential asymmetries in research and development or 
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production. Companies which realise the strategic importance of identifying, managing 
and leveraging core competencies from partner-firms are in an advantageous position to 
reap benefits in research and development or production.
Firms have to position themselves in an advantageous situation to establish leadership in 
their respective industries. In order to achieve this, firms would have to pick an optimal 
capability trajectory that will sustain first-mover advantages and an equally efficient 
resource trajectory that is unique (Miller, 2003). From firms to national industries, 
applying RBV is interesting once competitive advantage is adapted from an 
organisational level to a national focus. 
Developing national industries is often costly, time-intensive and requires extensive 
planning. Utilising the RBV is useful as traditional factor resources can be mapped onto 
physical, financial and human resources.  Thus if a firm or country makes an early move 
into an industry, it is possible to pre-empt competitors by applying RBV to identify 
critical raw material, locations and production processes (Hart, 1995). First-mover 
advantage will provide firms with a market niche and establish strong barriers against 
potential competitors. Likewise acquiring and managing an efficient resource trajectory is 
important especially when resources or initial factor endowments will greatly impact 
first-mover potential for firms and countries.
With adapting the RBV model to a national level, it may help to answer the global 
competitiveness question and provide useful insight in understanding how to develop 
new industries and inject new resources into current industries.
Global Biotech Clusters 
Biotechnology communities have increasingly emerged in recent years, especially in 
developed and developing countries like India and China. This shows global 
acknowledgment of the benefits offered by biotechnology. Prior to this current global 
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trend, biotechnology leaders by revenue, net income and market capitalisation were 
mostly in the United States of America. To date, most developed countries have 
biotechnology companies operating within its borders and these firms have established 
links with other biotechnology companies globally. As seen below in (Figure 1) countries 
coloured in brown rank highly in the Growth Competitiveness Index 2004-2005, World 
Economic Forum. Black circles represent select biotechnology and life sciences clusters.
Figure 1: Global Biotechnology Clusters Map
(MBBNet, 2009)
United Kingdom/ Ireland Continental Europe Middle-East Africa Asia Oceania
Glasgow-Edinburgh, Scotland Brussels, Belgium Israel Capetown, South Africa Beijing, China Brisbane, Australia
Manchester-Liverpool, England Medicon Valley, Denmark/Sweden Shanghai, China Sydney, Australia
London, England Stockholm/Uppsala, Sweden Shenzhen, China Melbourne, Australia
Cambridge-SE England Helsinki, Finland Hong Kong, China Dunedin, New Zealand
Dublin, Republic of Ireland Paris, France Tokyo-Kanto, Japan
Biovalley, France/Germany/Switzerland Kansai, Japan
BioAlps, France/Switzerland Hokkaido, Japan
Sophia-Antipolis, France Taipei, Taiwan
BioRhine, Germany Hsinchu, Taiwan
BioTech Munich, Germany Singapore
BioCon Valley, Germany Dengkil, Malaysia
New Delhi, India
Hyderabad, India
Bangalore, India
Table 1: Global Biotechnology Clusters by Region
(MBBNet, 2009)
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Several examples of biotech clusters are clearly depicted in the picture above are 
Medicon Valley in Denmark/Sweden; Biopolis in Singapore and US bioscience clusters 
in Cambridge, LaJolla, Research Triangle Park and the San Francisco Bay Area. These 
are some examples that demonstrated the transformational commercial and economic 
development opportunities which biotechnology represent.
Medicon Valley has emerged as one of Europe’s strongest biotechnology regions with a 
dense cluster of universities, hospitals and research institutes in pharmaceuticals and 
medical diagnostics (Burrill, 2008). Established in 1997, Medicon spans the Greater 
Copenhagen area in Demark and the Skåne region of southern Sweden with many 
universities, hospitals and companies within life sciences and medical technology. There 
are 100 biotechnology companies, 70 pharmaceutical companies, 130 medical technology 
and 15 clinical research organisations (CROs) (Medicon, 2009). With a diverse set of 
companies in the cluster, synergies in R&D, clinical research, production and sales and 
distribution are some examples of realised benefits. Biotechnology clusters are usually 
supported by government grants, subsidies, available laboratory-space, tax rebates and a 
favourable business environment (Ahn et al., 2008) to ensure growth and a thriving 
biotechnology industry. Companies in Medicon Valley are supported by low corporate 
taw, R&D expenses which are reimbursable and personal tax schemes for key 
biotechnology personnel (Medicon, 2009).
Asian Biotech Industry
This section will analyse the Asian biotechnology industry and gather insights on the 
industry, developments and aid overall understanding in the biotechnology business.
Biofuels
The Asian biofuel industry has emerged and started rapid development in recent years. 
Attracting foreign direct investments by overseas companies, issuing government licenses 
and approvals and development of biofuel plants are some growth initiatives undertaken 
by Asian countries to develop their own biofuel industry (Frost & Sullivan, 2007). The 
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Asian biofuel market can be segmented into supply and manufacturing components. The 
supply-side provides feedstock to manufacturers to mix with diesel to produce biodiesel 
or petroleum to produce bioethanol.  
Feedstock is the single largest cost component in biofuel production as the crop needs to 
be sown, cultivated, harvested and processed before being produced as biofuel. However 
Asia has ready access to low-cost feedstocks, lower labour costs and operations which 
gives them a comparative advantage over other global producers like the United States 
and Brazil (Frost & Sullivan, 2007). To acknowledge this advantage and potential export 
revenues, governments in countries like Malaysia, Thailand, Singapore and Indonesia 
have approved licenses and provided investment incentives to firms establishing biofuel 
production capabilities in their countries. It is significant now that the biofuel industry 
have grown into a main-stream industry and strategic source of income for respective 
governments. 
Demand for biofuel by countries in the European Union has increased export revenue 
potential as producers in the Asia region are able to offer their products at a lower cost. 
Countries that produce in excess of domestic demand are likely to export to other 
countries. The two largest biofuel manufacturers in Asia are China and India, in terms of 
market size, China has the third largest biofuel market globally after US and Brazil (Frost 
& Sullivan, 2009). 
The Asian biofuel industry has faced several challenges that have impacted growth to this 
industry. Issues of debate have raised concerns over the “food versus fuel”, this means 
should edible vegetable crops be used for fuel or food; burning and clearing of native 
forests for more arable land and replacing current food crops like rice, fruits or vegetables 
with cash crops like palm oil and rapeseed for biofuels. 
An illustrative example is Gushan Environmental Energy Limited, a China-based 
company founded in 2001 and listed on the New York Stock Exchange in 2007 with 
annual revenue of over US$140 million and 350 employees (Gushan, 2008). Gushan is a 
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leader producer of biodiesel and related products in China with current annual production 
capacity of 400,000 tons of biodiesel. Through economic transformation of China’s 
economy, urban households are one example that has managed to experience an increase 
in income and their spending expenditure has grown. Vehicle-ownership is one of the key 
drivers of energy-consumption, vehicles in China has increased from 11.5 million in 1994 
to 41.8 million in 2004. 
In view of China’s expanding economy and corresponding demand for energy; and 
increase in Europe and United States biodiesel consumption, producers like Gushan will 
continue to experience growth and if their prices remain competitive and scientific 
discoveries continue to prove biofuels are a useful interim alternative to reduce carbon 
dioxide emissions. China’s economy, measured through Gross Domestic Product (GDP) 
has expanded at an annual rate of 11% especially in the last 10 years. Gushan has its own 
R&D department which developed their current biodiesel manufacturing technology. 
This process is currently protected under patent on Intellectual Property Rights. This 
process utilises vegetable oil, used cooking oil and offal which are easily available in 
China and at low costs. This helps Gushan maintain cost-competitive and able to compete 
in distant markets. 
Biopharmaceuticals
Asia’s biopharmaceutical industry has been growing and making significant progress in 
recent years ever since their local governments perceived life sciences as a driver of 
economic development. However they are latecomers to commercial life sciences as
compared to the United States and European Union (Gwynne, 2004; Ernst & Young, 
2004). Nevertheless many foreign companies are attracted to Asia. Some reasons for 
growth are government financial incentives like tax-cuts/breaks, lower overheads and 
close geographical proximity to neighbouring countries like China and India which have 
human population of over 1 billion people. 
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One advantage of being latecomers to life sciences is that for an expensive venture with 
high failure rates, the risk which is extremely high. This is minimised to a certain extent 
because of returning expatriates with experience in the Western biopharma industry and 
they bring knowledge of its standards and processes, new ideas and money when they 
return to their respective homelands (Ernst & Young, 2004). The ongoing developments 
of new medicines require extensive screening of initial candidate substances and require 
long periods of time (Gurau, 2004).Therefore playing catch-up by Asia’s numerous 
biopharmaceutical contenders is a positive first-step forward.
The South-East Asian market is emerging as a growing market for biopharmaceuticals 
and a research-driven environment for R&D. Thailand, Malaysia and Singapore are 
examples of how biopharmaceuticals have experienced constant annual growth averaging 
5-6% (Espicom, 2008). The respective governments have acknowledged 
biopharmaceuticals and biomedical sciences as an integral driver of future wealth 
creation and to promote investment. Key initiatives undertaken and pursued range from 
strategies to develop a bioeconomy, demonstrate government-led commitment, policies 
to regulate biotechnology-business environment, infrastructure to support companies and 
R&D; and provide funding or tax incentives to attract foreign investment. 
Biopharmaceuticals in other parts of Asia like India and Japan are established as the 
biggest biotechnology sector. Biopharmaceuticals comprise more than 70% of India and 
Japan’s biotechnology industry. To date, Japan’s biopharmaceuticals industry is the 
world’s second largest market valued at US$64 billion. The growth in Japan’s 
biopharmaceuticals comes from a rapidly-aging population, declining birth-rates, longer 
life-spans, and increasing costs for providing healthcare to the elderly. 
An illustrative example is Japan’s largest biopharmaceutical company Takeda 
Pharmaceutical Company Limited, established since 1781 as a traditional medicines 
company and became in 1925 with R&D facilities, manufacturing plants and various 
business operations. Takeda has R&D facilities in Japan, United States, Singapore and 
the United Kingdom; production facilities in Japan, Italy, China and Indonesia, hiring a 
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total of 15,717 employees with annual revenue of US$13.748 billion (Takeda, 2009). 
Takeda’s mainstay product is Actos, a drug targeted at Type 2 Diabetes, a disease which 
reduces insulin sensitivity in the body and requires injected insulin. Diabetes is an 
increasing problem in Japan as estimates by the Ministry of Health puts the amount of 
diabetic patients at 7% of the total population of 127 million people. Diabetes is a disease 
which causes poor healing of wounds, nerve damage, double-risk of cardiovascular 
diseases and retinal dysfunction or failure (US FDA, 2009). Diabetes is classified as a 
life-style disease and factors like obesity, limited exercise, smoking and poor diet are 
some factors that result in the disease. This disease is increasingly prevalent amongst 
developed nations as Takeda sales revenue in Actos, have experienced compound annual 
growth between 10-15%  since 2001, annual revenue is worth US$326 million in Europe, 
US$2.8 billion in the United States and US$420 million in Japan (Takeda, 2008). 
Nutraceuticals
The Asian nutraceutical product market showed that the region accounted for 44% of 
global sales and is the single largest market, exceeding North America and Europe (Food 
& Drink, 2006; Frost & Sullivan, 2004). Japan was the largest market in Asia, worth 
US$11.4 billion and the second-largest globally after the United States; and China, 
second-largest in Asia and third-largest globally, was worth US$5.9 billion. Including 
countries like South Korea and Taiwan, both valued at US$1.9 billion and US$1.3 billion 
respectively, the Asia market is worth at least US$20.5 billion. 
Asia’s perception of nutraceuticals have shifted in recent decades vis-à-vis changing 
lifestyles and increased awareness of a balance and nutritious diet. The general 
population in Asia are aware of healthcare costs, lack of nutrition in processed foods and 
increased public-education and awareness of healthy living. Numerous companies have 
targeted this change in consumer preference and offer nutraceuticals in various forms 
from vitamins, health supplements and fortified foods. 
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The general Asian diet is considered to be naturally healthy due to dietary intakes of fish, 
fresh vegetables and chicken. However increased westernisation of diets has resulted in 
more red-meat, dairy and processed-food consumption, which raises the need for 
nutritional supplements. Nutraceuticals in Asia are dominated by nutritional supplements 
such as herbal products since the region has a long history of traditional and herbal 
medicines or cures. According to a study in 2004 by Frost & Sullivan, vitamins and 
natural supplements make up 70% of the Asian nutraceuticals market as compared to 
35% to North America and the European market. This view is supported as tonics 
account for US$4 billion in sales in 2006 and is the single most popular nutraceutical 
category (Food & Drink, 2006).
An illustrative example is Cerebos Pacific Limited, with history dating back to 1892 but 
modern history from 1981, is a Singapore-based diversified-nutraceutical company with 
annual turnover of US$540 million and over 2,478 employees (Cerebos, 2009). Cerebos 
has corporate headquarters based in Singapore and provides management services to 
subsidiaries in the region. The mainstay product of Cerebos is BRAND’s liquid which are 
herbal soups packaged into bottles that can be drank either chilled or heated. This product 
has established market-share in Asian markets like China, Singapore, Taiwan, Thailand, 
Malaysia and Hong Kong which Cerebos earns over US$282 million annually. This 
product also makes up almost 52% of Cerebos annual turnover and has an annual 
compound growth rate of 5.6%. BRAND’s product range targets children, school-going 
children, working adults and the elderly. Well-known Asian herbs like cordyceps, 
ginseng and bird’s nests are some main ingredients of BRAND’s liquid health 
supplements. Other herbs also form part of the product range which caters to varying 
tastes and attractive packaging to market the product. The inclusion of such herbs into 
modern applications like bottling, customise flavours and attractive packaging 
demonstrates the evolving nature of consumer taste and preference and how a 
nutraceutical company like Cerebos has to keep up with times.
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Agriculture
A 2007 United States Department of State study (USINFO, 2007) of the Asian 
agriculture biotechnology industry proposes that there will be more research to improve 
crops to improve growing needs for food and fuel to feed rising populations and energy 
requirements. Genetically modified or transgenic crops are increasingly approved by 
Asian countries and extensive cultivation has commenced in countries such as China, 
India, Pakistan, Japan, Thailand, Philippines and Vietnam. Commercial adoption of 
transgenic crops is one of the main driving factors of the rapid adoption and diffusion of 
biotechnology in the Asian region (AgBioWorld, 2000; Asian Development Bank; 2001; 
USINFO, 2007). 
Asian leaders of agriculture-biotech are India and China with the highest number of 
hectares planted with transgenic crops. India and China have a combined total of 7.1 
million hectares of cultivated transgenic crops but are significantly lesser as compared to 
the United States of 54.6 million hectares or Argentina at 18 million hectares (USINFO, 
2007). Transgenic crops that have been cultivated are rice, cotton, corn, oil palm and 
canola; of which cotton, corn and canola have been planted in significant areas of Asia. 
These crops have an important role in Asia as a food and fuel source. 
Countries like China, Philippines, Malaysia and India have invested heavily to develop 
their agriculture industries through utilising biotechnology to improve yields, reduce 
pesticides and increase nutrition in crops. Government initiatives have helped developed 
agriculture biotechnology through establishment of research institutions, biotech clusters, 
strategic alliances between neighbouring countries to co-develop a particular vaccine or 
cash-crop and guidelines for a regulatory framework to commercialise transgenic crops 
for import and export (Teng, 2008; Bar Chronicle, 2000; Asian Development Bank; 
2001). 
An illustrative example is Yasheng Group, China’s leading biotech enterprise, established 
since 1970s with annual revenue of US$656 million and employing more than 15,000 
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workers in regional offices in China and the United States (Yasheng, 2009). Yasheng’s 
51 products are sold in China and other regional markets like Europe, Canada, Australia 
and Pakistan, with major brands like Tsingtao Beer and MacDonalds as their strong 
customers (Yasheng, 2009). Yasheng capitalised on biotechnology in 1998 to 
supplement their current capabilities in agriculture and developed superior crops like 
cotton which yield more and require lesser water and nutrition; and hybrid seeds that are 
disease-resistant and able to be cultivated in high altitudes. Strategic alliances with 
Mexico’s leading Wheat and Corn Improvement centre in 1999 has resulted in R&D 
success with over 2178 varieties of wheat, barley, corn and other related field crops 
developed. This change in direction and development of biotechnology has been flowed 
over to the creation of support services like a high-tech agricultural park that has been 
fully-operational since 2005. The company has also established two educational institutes 
with more than 200 teachers and lecturers and approximately 2,000 students. Subjects 
taught in these institutes focus on technology and agriculture, acting as a R&D facility for 
Yasheng’s commercial operations and as a training resource for potential employees. The 
macro outlook for Yasheng’s activities appears sustainable as China’s growing 
population, increasing demand for food and fuel and favourable policies from the central 
government has created a favourable environment to grow its operations and businesses. 
Long-term growth plans is to capitalise on Yasheng’s market leadership in China’s 
agriculture industry to fund global acquisition or mergers and acquisitions.
Medical Devices & Diagnostics
Asia’s diagnostic and medical devices industry has grown rapidly in past years, and has 
attracted numerous American and European companies to outsource manufacturing of 
medical devices and a potential export market (Gross, 2007; Delporte, 2006). Factors like 
lack of domestic competition in Asia, major disease outbreaks, and increasing health 
awareness are cited as drivers of a growing diagnostics industry (Chigullapalli & 
Tadulwadikar, 2007; Frost & Sullivan, 2008; Frost & Sullivan, 2007c).
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The single largest market is Japan, estimated value at US$10 billion, with China, 
estimated at US$ 6 billion, India at US$1.5 billion and South Korea at US$1.4 billion. An 
interesting phenomenon discovered was Asian medical device producers from Japan, 
China and South Korea have started to move into Latin America markets (Frost & 
Sullivan, 2008a). These producers have focused largely on patient monitoring and 
ultrasound, which are both essential components of healthcare. Asian manufactured
products are often associated as low-cost solutions with reasonable quality. This 
perception is due to years of outsourcing by European and American companies which 
have enabled these Asian producers to manufacture similar products at heavily-reduced 
costs. 
An illustrative example is Olympus, Japan-based heavily-diversified consumer, medical 
and industrial company, established since 1919 with annual revenue of US$10.75 billion 
and 35,772 employees (Olympus, 2008). Olympus started producing cameras and 
gradually progressed onto microscopes, endoscopes and diagnostic systems. Olympus 
recently acquired Gyrus Group PLC in February 2008, with approximately 1,400 
employees in 13 world-wide locations. Gyrus is a medical equipment company based in 
the United Kingdom, listed on the London Stock Exchange with annual net sales worth 
US$323 million. This recent acquisition is part of Olympus’ basic strategy of adding new 
capabilities in its Medical Systems Business. Gyrus specialises in endoscopes, which is 
used in minimally invasive procedures without opening the abdominal cavity. This 
process is increasingly popular as it contributes to easing physical stress on patients and 
reduces hospital stays. To date, endoscopes are used in general surgeries, gynaecology 
and urology. 
This acquisition opens up product and regional transition synergies for Olympus. The 
regional strategy by Olympus is to use Gyrus’ established reputation in the North 
American market which amounts to 80% of annual turnover to sell Olympus products 
and sell Gyrus’ products. Utilising Gyrus’ capabilities in endoscopes will increase 
Olympus’ surgical business scope and add to new products line-ups. This will aid 
Olympus’ bid to establish a leadership position in the urological and gynaecological 
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fields, along with tapping Gyrus’ established relationships with doctors, hospitals and 
other research institutes. Olympus estimates after the acquisition with Gyrus, Olympus 
will have over 50% share of the global market share for urological endoscopes, spanning 
across Japan, United States and Europe. 
Asian Biotech Clusters
This section will analyse three Asian biotechnology clusters within the context of cluster 
theory and understand how these clusters function and support the companies.
Japan
The Hokkaido biotechnology cluster is situated in Japan established in 1999 with 34 
companies initially; and has grown to 94 companies in 2006. Annual turnover is 
estimated at US$263 million with 938 employees across member companies 
(HokkaidoBIO, 2008). The Hokkaido biotechnology cluster consists mostly of 
agriculture and food, and medical care and pharmaceutical industries. Both industries 
account for 70% of the cluster. The cluster was launched by the Hokkaido Bureau of 
Economy, Trade and Industry with the aim of promoting the formation of an information 
and biotechnology industry cluster. 
The cluster focuses on growing and developing university-launched ventures and aiding 
small to medium enterprises. Companies within the cluster have established mutual 
relationships with one another on transaction and joint research and merging various 
capabilities together for new product development. The number of university-launched 
ventures average 40 new ventures per annum.
Numerous efforts have been undertaken to collaborate with other institutions like trading 
firms, venture companies and manufacturers. The notion is without these support 
providers, lack of funding or manufacturing capabilities might limit growth. Therefore 
the Hokkaido cluster has a formal platform which seeks to attract investments by 
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promoting the cluster nationally and internationally and establish multi-layered networks 
with universities, research institutions and biotechnology clusters.
Singapore
The Biopolis is a custom-built biomedical research and development cluster situated in 
Singapore. Construction began in 2003 and planned to be completed in 4 phases 
(Biopolis, 2007). The Biopolis is situated next to the National University of Singapore 
(NUS), a globally-renowned institute and other education and service providers like 
polytechnics, ministry of education and hospitals. There are nearby clusters like the 
Singapore Science Park and Fusionopolis, which is a R&D centre for electronics and 
technology. Locating the Biopolis close to other creative clusters allows synergies like 
agglomeration, tapping into capabilities from other industries and collaborating to 
develop products. 
Biopolis is an initiative to provide space for biomedical research and offer a platform for 
collaboration between the private sector and public research institutes. Phases 1 and 2 are 
completed with nine buildings. These buildings house public sector research institutes 
and private companies like GlaxoSmithKline and Novartis. Current research is on 
neurology and immunology and Biopolis is also self-contained with accommodation for 
over 2,000 personnel.
Hong Kong
The biotechnology industry in Hong Kong is an emerging sector with an estimated 400 
companies. Healthcare companies with businesses in pharmaceuticals, nutraceuticals and 
medical diagnostics form the majority of companies in Hong Kong. Most of Hong 
Kong’s biotechnology companies have substantial business dealings in mainland China 
and perceives it to be their largest export destination (ITC, 2009). 
The main biotechnology cluster, Hong Kong Science Park, completed in 2005, is a 
dedicated commercial area for more than 200 biotechnology companies where a 
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Bioinformatics Centre provides R&D facilities in therapeutics, medical diagnostics and 
other biopharmaceutical-rated research (HKSTP, 2009). Other current tenants in the 
cluster are companies in electronics, precision engineering, information-technology, 
business consulting and law. These tenants provide support services to biotechnology 
firms in the cluster through manufacturing, accounting, marketing, business advisory, 
intellectual property protection, R&D and other value-added services. New start-up 
benefits like access to university resources, technology, aid reimbursement or expense 
subsidisation up to US$110,000 for a period of 4 years and rent-free occupancy for 4 
years are available to assist biotechnology companies. These benefits are made available 
to assist biotechnology companies to achieve R&D to commercialisation success.
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Malaysian Economy
This section will analyse Malaysia’s overall economy within the context of existing 
capabilities and capacity building.
Malaysia is a former British colonial settlement situated in South-East Asia and shares 
borders with Thailand, Indonesia and Brunei. The country first gained independence in 
1957 and formed the Federation of Malaysia which consisted of various Malaysian states.
Malaysia has a population of 27.7 million people living in both East and West Peninsular 
Malaysia (MIDA, 2008). The major ethnic groups are 50.4% Malay, 23.7% Chinese, 
11% Indigenous, 7.1% Indian and 7.8% others (CIA World Fact Book, 2008). Malaysia 
has transformed itself gradually from a raw materials producer of agriculture and primary 
commodities to a multi-sector economy spurred on by technology, knowledge and 
capital-intensive industries. 
The government has launched economic initiatives like the Ninth Malaysia Plan (2006-
2010), National Biotechnology Policy and Third Industrial Master Plan (2006-2020) to 
propel and grow Malaysia’s economy and provide more value-added products and 
services. Such policies give emphasis, directives and targets for long-term growth and 
progress, which will be covered later on in this paper. 
The Gross Domestic Product – composition by sector shows agriculture at 9.9%, industry 
at 45.3% and services at 44.8% (CIA World Fact Book, 2008). Major exports by 
Malaysia are manufactured electrical and electronic products, chemicals, machinery, 
palm oil and rubber (CIA World Fact Book, 2008; MIDA, 2008). Major imports are 
vehicles, iron and steel products, petroleum, plastics, processed food and beverages and 
industrial supplies (CIA World Fact Book, 2008; MIDA, 2008). 
Malaysia is currently the world’s largest producer of rubber and tin and is a leading 
exporter of semiconductor devices, computer hard disks and other electronic products. 
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This is a direct result of growth in its manufacturing sector which accounted for 30.3% of 
Malaysia’s GDP in 2007 (MIDA, 2008). Malaysia’s rapid industrialisation is a result of 
policies encouraging foreign direct investments (FDI), an educated multilingual 
workforce and beneficial economic policies. 
Malaysia’s GDP per capita increased rapidly from 1990-2005, and is currently classified 
as an upper-middle income economy by the World Bank (World Bank, 2009). From 
1990-2005, Malaysia’s average income increased from US$5,284 to $10,318 with an 
annual growth rate of 4.6%. An important thing of note, a study conducted by Frost & 
Sullivan in 2006 showed that Malaysia’s healthcare spending ranks the 5th highest in Asia 
and this has led to new demand for healthcare products and services (Figure 2). 
Malaysia Healthcare Spending Growth Rate, 2006
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Figure 2: Malaysia Healthcare Spending Growth Rate
(Frost & Sullivan, 2006)
Malaysia Bioeconomy
Malaysia has prioritised biotechnology and its benefits to bring progress to its people 
financially and socially. South-East Asia has been developing biotechnology industries 
and capabilities rapidly in the last few years. Researches have started on areas of 
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significance to the Asia culture and region. For example, agro-biotechnology has focused 
on rice, and other tropical crops for the herbal medicine industry. Biomedical research 
has also focused on diseases common to Asian people in tropical regions like Malaria, 
Typhoid and Dengue (Frost & Sullivan, 2001). Throughout South-East Asia, the trend 
has been to strengthen research facilities, biotech parks and seeking foreign investments 
to enhance growth in the bioeconomy. 
The Prime Minister of Malaysia Abdullah Badawi made a speech in 2006: “It is not 
about placing big companies here to operate. Our approach has to be different and we 
have to develop our unique strengths and capitalise on them with products that have 
comparative advantages” (Fierce Biotech, 2006).
The Malaysian government has announced the 9th Malaysia Plan, with an allocation of 
Ringgit$2 billion (US$553 million) for the biotechnology and life sciences for research 
and development and industry development. This allocation complements current private 
sector funding in the biotechnology industry as the government has set it out to be a new 
driver of economic growth in Malaysia. A life-sciences fund has been started up as 
venture capital to fund pioneering biotechnology companies. Numerous initiatives have 
also been underway to formulate institutions and companies. Malaysia Biotech 
Corporation (BiotechCorp), a government-linked company with key roles in developing 
the biotechnology industry and providing financial aid to biotechnology companies to 
assist them with commercialising discoveries (BIOTEK, 2009). 
Biotech Corporation has targeted specific growth areas in Malaysia. The three focus areas 
are Agriculture, Healthcare and Industrial (refer to Figure3). These specific areas are 
crucial to Malaysia’s long-term growth in terms of comparative advantage and increasing 
global demands like renewable energy sources, drug-resistant diseases and healthier 
lifestyles.
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Figure 3: Biotechnology Focus Areas
(Biotechcorp, 2009)
Malaysia is largely an agricultural-based country with primary produce, for example: 
vegetables, rice, meat and fruits. Therefore agricultural and food biotechnology have 
emerged as the main biotechnology focus of government and private sector. Agriculture 
biotechnology has impacted industrial and food crops. Crops like oil palm are 
increasingly cultivated by Malaysia as a food source with industrial purposes such as
renewable fuel, chemicals and in pharmaceutical products. Oil palm is produced in 
estates owned by plantation companies. The fruit bunches are harvested by hand and the 
oil extraction process is done at mills often located nearby the plantation. Investing in oil 
palm cultivation is a long-term commitment as the oil palm tree will take at least thirty 
months to mature in order to produce sufficient fruit for harvesting (Basiron, 2007). An 
oil palm has an economic life-span of 25-30 years, of which due to intensive research 
over the years have ensured consistent high yields and agronomy best practices (Basiron, 
2007). Today’s major palm oil producing countries are Indonesia and Malaysia which 
account for over 85% of the global oil palm output. The oil palm can only survive in 
tropical climates.
According to Frost & Sullivan (2008), the Malaysian Pharmaceutical outlook, Malaysia 
is likely to grow to be a leader in the global pharmaceutical industry. Key reasons that 
were given are an increased reputation as a medical provider and supplier; in medical 
tourism, Malaysia offers low-cost and good quality medical treatment; and the generic 
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medicines market which Malaysia has been focusing on is a booming industry globally 
(Biospectrum, 2008). According to a study done in 2005 in the United States, the generic 
medicines industry represented more than 56 percent of prescriptions dispensed (Jaeger, 
2006). This percentage leads to annual sales of US$22 Billion in the generic 
pharmaceutical industry. Research in other areas of medical biotechnology has resulted in 
development of diagnostic kits for Dengue Fever and several other tropical diseases. 
The National Biotechnology Division (BIOTEK) was established in 2005, a division 
under the Ministry of Science and Innovation (MOSTI). BIOTEK’s roles are to lead the 
biotechnology development and establish biotechnology in Malaysia (BIOTEK, 2009a). 
Other roles include R&D, developing international linkages between the domestic and 
international biotechnology industry, research funding and; providing relevant education 
and training to human capital for biotechnology growth.
In other Malaysian states, there has been development of research institutions, in part of 
the government’s numerous grants but also to attract foreign investment into their 
regions. An example of this would be Malaysian state of Melaka, which created a 
biotechnology institute, Malacca Biotech, in 2005 to focus on farming and seafood 
aquaculture. Chief Minister of Melaka Mohd Ali Rustam commented: “After the initial 
focus on agriculture and food biotechnology, the institute will produce plant extracts for 
usage in nutraceuticals” (Daily Express, 2005). 
The Malaysian state, Sabah, in 2006 formulated a ten-year action plan from 2006-2015; 
drawn up with policies and strategies to develop a biotechnology hub in the state. Chief 
Minister of Sabah Musa Aman commented “biotechnology will accelerate the state’s 
transition to a bioeconomic region, exporting value-added products instead of raw or 
semi-processed ones...a viable bio-industry enterprises can be established with Sabah’s 
factor endowments.” Strategies for the state will include private sector participation to 
commercialise innovations, allocate agro-technology parks and clusters (Daily Express, 
2005; Daily Express, 2007). The Chief Minister, Musa Aman also assured various 
stakeholders like government agencies, research institutions and the private sector; of the 
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state’s ambitions and determination to succeed and will provide support and necessary 
assistance to develop the biotechnology sector in Sabah. 
For Malaysia, there are a series of plans to develop their bioeconomy. During BIO 2007, 
Malaysia signed a deal with France-based Nanobiotix for an exclusive worldwide license 
in nanotechnology platform for non-cancer purposes. Also at BIO 2008 in Malaysia, six 
biotech contracts worth Ringgit$1 billion (US$276.5 million) was signed. Foreign 
companies from the United States of America, Italy, India, France and South Korea were 
involved. Domestic company like Malacca Biotech, mentioned earlier is one of the six 
companies to strike a contract with a foreign company like Vivo Biotech (India) to 
commercialise biotherapeutics, to produce drugs for diseases such as diabetes and cancer 
(The Star Online, 2008). To date, Malacca has attracted close to Ringgit$2.5 billion 
(US$691 million) in foreign biotechnology investments.
Malaysian Government Strategies for biotech sector growth
This section will analyse Malaysia’s strategies to develop a bioeconomy within the 
context of economic policies and growth schemes; and will assist in overall 
understanding.
Ninth Malaysia Plan
“In the context of building our prosperity, the Ninth Malaysia Plan represents one of the 
most significant Malaysia Plans in our country’s history”
                                                                           YAB Dato’ Seri Abullah Ahmad Badawi
                                                                          Prime Minister of Malaysia
At the tabling of the motion on the 
Ninth Malaysia Plan 2006-2010
31st March, 2006
In March 2006, the Ninth Malaysia Plan which is the first of three Malaysia Plans to 
achieve Vision 2020 (EPU, 2008). This phase of developments represent Malaysia’s 
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ambition to become a developed nation by 2020. The Plan which runs from 2006-2010 
consists of policies and key programmes that will be essential for Malaysia to attain and 
accomplish in order to fulfil the Plan’s objectives during this time frame. There are 
several thrusts or steps to be achieved in order to realise this dream. They are:
9th Malaysia Plan
 Thrust 1 – To move the economy up the value chain 
 Thrust 2 – To raise the capacity for knowledge and innovation and nurture ‘First 
Class Mentality’ 
 Thrust 3 – To address persistent socio-economic inequalities constructively and 
productively
 Thrust 4 – To improve the standard and sustainability of quality of life
 Thrust 5 – To strengthen the institutional and implementation capacity
In these thrusts, there are several initiatives. Firstly, the government had realised there 
was a need to establish new sources of wealth-generation; namely through biotechnology 
and information-communication technology. Given the changing domestic and global 
economic landscapes, a plan is needed to enhance national competitiveness and 
resilience. Effort and support will be given to develop the biotechnology industry as a 
new driver of economic growth. 
The government has also ear-marked several aspects of necessary improvements like the 
investment regulatory framework, development of relevant infrastructure, improve access 
to funding, increase rate of research and development (R&D) commercialisation, 
increasing the number of skilled biotechnology workers and researchers and attract 
foreign research partners and institutes (EPU, 2006). The Malaysian government will 
allocate Ringgit$2 billion (US$553 million) to aid the development of biotechnology and 
to complement private sector funding. The focus in the biotechnology industry will be in 
agriculture, health care, industrial, bio-informatics and diagnostics.
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The government is also committed to strengthening R&D, science and technology as 
another front to further the pursuit of biotechnology. The realisation that Malaysia needs 
to acquire significant capabilities in science and technology has led to increase in the 
public sector budget allocation to Ringgit$3.9 billion (US$1.08 billion), twice the amount 
allocation under the previous Eighth Malaysia Plan (EPU, 2006). By 2010, the 
government aims to eventually spend 1.5% of the country’s GDP on R&D and encourage 
research as the basis of developing and deepening knowledge. The Science and Techno 
Funds will be established to ensure expenditure of R&D will be maximised through 
prioritising and focusing on specific and promising R&D efforts and pursue 
commercialisation of successful R&D discoveries.
National Biotechnology Policy
“If the 20th century was the age of chemistry and physics, the 21st century will be known 
in history as the era of life sciences. Man has, of course, explored and utilised biological 
processes for centuries.”
YAB Dato’ Seri Abullah Ahmad Badawi 
Prime Minister of Malaysia
At the launch of BioMalaysia 2005
28th April 2005
                                                                                                               (Biotechcorp, 2005)
The biotechnology industry has expanded at a rapid pace due to various government 
initiatives and policies. The Malaysian government recognises that biotechnology can 
bring improvements in Malaysians’ quality of life, propel knowledge creation and 
innovation and is a crucial element in the country’s quest to ascend the economic value-
chain. With the application of biotechnology, additional value can be unravelled in 
traditionally strong sectors especially in its agricultural industry. This potentially can 
create spill-over effects in new and upcoming sectors such as healthcare, nutraceuticals 
and industrial bio-progressing (NBP, 2005). The government view Malaysia is endowed 
with a wealth of resources that is essential to the development of biotechnology. Varied 
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biodiversity can be found throughout Malaysia and the country has developed its 
resource-based industries. 
This landmark policy contains nine thrusts which outline the direction and measures 
offered by the government towards developing biotechnology for wealth creation and 
national well-being (NBP, 2005). 
They are: 
National Biotechnology Policy 2005
 Thrust 1 – Agriculture Biotechnology Development
 Thrust 2 – Healthcare Biotechnology Development
 Thrust 3 – Industrial Biotechnology Development
 Thrust 4 – R&D and Technology Acquisition
 Thrust 5 – Human Capital Development
 Thrust 6 – Financial Infrastructure Development
 Thrust 7 – Legislative and Regulatory Framework Development
 Thrust 8 – Strategic Positioning
 Thrust 9 – Government Commitment 
Thrust 1 of the Biotechnology Policy seeks to transform and enhance the value creation 
of the agricultural sector through biotechnology. Thrust 2 seeks to capitalise on strengths 
of Malaysia’s biodiversity by commercialising discoveries in health-related natural 
products and bio-generic drugs in nutraceuticals and biopharmaceuticals. Thrust 3 will 
leverage through Malaysia’s current strong manufacturing sector by increasing the 
current opportunities in bio-processing and bio-manufacturing. These thrusts epitomises 
one of the main principles behind the Biotechnology Policy, which is to leverage 
Malaysia’s existing capabilities and to add value to aid the country’s ascension up the 
economic value-chain (NBP, 2005). These initial biotechnology developments will grow 
the country’s agriculture, healthcare and manufacturing to a higher stage.
Thrust 4 seeks to establish biotechnology centres of excellence throughout the country 
where research teams of various disciplines can cooperate in coordinated initiatives. 
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Resources have been channelled into developing centres of excellence such as Mardi and 
Universiti Putra Malaysia for agricultural technology, Universiti Kebangsaan Malaysia 
for genomics and molecular biology and Biovalley in Dengkil for pharmaceuticals and 
nutraceuticals (BM, 2005). In Thrust 5, the plan is to build the nation’s human capital in 
biotechnology via education and training. As outlined earlier in the Ninth Malaysia Plan, 
there will be a boost in the education sector. This is also known as the National Education 
Blueprint 2006-2010. 
According to a press release by Education Minister Datuk Seri Hishammuddin Tun 
Hussein on a new curriculum to be released into primary schools “We need changes in 
curriculum to bring about changes…therefore new areas of focus will be on literacy in 
science and technology” (The Star Online, 2007). In Malaysia’s institutes of higher 
learning, 13 universities offer biotechnology programs and 12 universities offer chemical 
engineering programs. This amounts to about 3,000 undergraduates studying 
biotechnology and related courses annually. The government estimates over the next five
years, there will be an estimated 23,000 research personnel and more than 5,000 R&D 
scientists ready to be employed into the biotechnology industry (MIDA, 2006)
Thrust 6 is all about applying funding to commercialise discoveries from ‘lab to market’. 
Incentives are also given to encourage participation from academia and private sector 
institutes. The Malaysian government intends to participate in every sector of the 
biotechnology value-chain, thus giving balanced attention to all ventures and avenues of 
interests. As mentioned earlier, the key areas were to increase R&D and participation 
from academia and the private sector. To achieve these targets, the Malaysian 
government intends to establish dedicated matching grants for biotechnology R&D and 
commercialisation ventures. Financial support will also be given to companies trying to 
apply for patents. To further encourage private sector participation, tax reductions or 
relief of up to 100% on qualifying biotechnology investments will be granted. 
Biotechnology companies will also enjoy tax incentives prepared by the government.
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Thrust 7 of the policy is to improve Malaysia’s innovation system. This takes into 
consideration of reviewing the legal and regulatory framework on intellectual protection. 
Intellectual protection gives researchers a share in the ownership of their discoveries and 
in any monetary rewards derived from their work (NBP, 2005). This will be covered in 
detail in later segments.
Thrust 8 sets out to establish a global reputation for Malaysia’s biotechnology industry. 
Biotechnology has developed into global commerce as firms do not operate in only one 
country but often cooperate with other firms globally for R&D and production. Therefore 
to build its reputation, the Malaysian government has two tie-up programs with the 
Massachusetts Institute of Technology (MIT) and the California Institute for Quantitative 
Biomedical Research (QB3). The former, a 5-year research collaboration known as the 
Malaysia-MIT Biotechnology Partnership program, will bring together 200 researchers in 
Malaysian institutes and 27 researchers from MIT to focus on medicinal plants and palm 
oil (Biobusiness Channel, 2007). The latter is an advanced training program at QB3 for 
senior Malaysian scientists and administrators and students are also given opportunities 
to pursue their thesis or postdoctoral research at the institute.
The Malaysian Biotechnology Corporation (Biotech Corp) was setup as part of the 
government’s commitment in Thrust 9. Biotech Corp is under instruction by the 
Implementation Council headed by Malaysia’s Prime Minister Abdullah Badawi. Biotech 
Corp is also tasked with identifying worthwhile ventures in biotechnology R&D and 
commerce, assisting start-ups with financial and developmental services. The corporation 
will work closely with all relevant agencies in order to grow Malaysia’s biotechnology 
industry. 
Malaysian Biotech Fund and Venture Capital
Funding is provided by Malaysian Biotechnology Corporation (BiotechCorp) and 
Malaysia Technology Development Corporation (MTDC). MTDC is an agency under the 
Ministry of Science, Technology and Innovation (MOSTI), started by the Malaysian 
Government in 1992 to lead development of technological businesses in Malaysia. Its 
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original roles were to promote and assist commercialisation of local research and invest 
in new ventures to bring in new technologies (Biotech, 2009). MTDC has since become a 
leading venture capital outfit and spearheading the venture capital market in Malaysia. To 
date, MTDC has established six private equity funds with a combined funding of 
RM$202 million (US$56.07 million). These private equity funds are targeted at growth 
areas in technology, agriculture, timber and economic growth in East Malaysia (MTDC, 
2009).
There are five sources of funding made available by BiotechCorp and provided for 
biotechnology companies in Malaysia. They are as mentioned:
 Technology Acquisition Programme
 Biotechnology Commercialisation Grants
 Biotechnology Entrepreneurs Development Fund
 Intellectual Property (IP) Research and Management Programme
 Venture Capital, co-share with Malaysian Technology Development 
Corporation
Technology Acquisition Programme provides financing for biotechnology companies 
and individuals intending to purchase present and emerging products or process 
technologies for use in biotechnology. The criteria to qualify for such funding includes 
the direct expenditure incurred for acquiring the product or process technology. 
Biotechnology Commercialisation Grants provide funding to priority biotechnology 
areas and seeks to bridge gaps between public and private sector funding. Under this 
grant, there are three types of funding available. Firstly, Seed Fund is for financing start-
up costs in setting up biotechnology companies. This funding also aids commercialisation 
and development of biotechnology projects and R&D findings in priority and core areas. 
Secondly, R&D Matching Fund provides matching funds for current or new R&D 
initiatives to develop new or improve existing products, processes and technologies to 
enable further development and future commercialisation. Lastly, the International 
Business Development Matching Fund promotes the expansion of companies with 
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Bionexus status into entering the global market. This fund also provides to support 
Bionexus firms internationally and efforts to compete globally.
Biotechnology Entrepreneurs Development Fund provides biotechnology individuals 
especially entrepreneurs with the necessary skill sets and knowledge to start-up new 
biotechnology ventures. Potential entrepreneurs are also supported on how to seek 
funding and business management. Typically all new ventures will be supported 
especially the establishment of start-ups and development of small to medium enterprises 
(SMEs). Other aims of this fund include enhancing the competitiveness of entrepreneurs 
and their enterprises, business sustainability and training serial entrepreneurs.   
Intellectual Property (IP) Research and Management Programme is introduced to 
educate and increase awareness of existing IP networks and channels. Such information 
is disseminated through seminars, workshops and conferences on IP management. IP 
protection has proven to be an integral part of the biotechnology industry. IP protection 
grants the research or company temporary monopoly over their R&D discoveries and 
allows commercialisation and future product development. This will be covered in later 
sections of this paper.
  
Venture Capital has become an important source of financing for technology-intensive 
companies and the Malaysian government has developed a list of government-backed and 
private venture capital companies to support start-ups. An example would be the 
Malaysian Life Sciences Fund which is a cooperative effort between the Malaysian 
Technology Development Corporation Sdn Bhd (MTDC) and Burrill & Co.; an American 
life sciences bank based in San Francisco, California (MTDC, 2008). It was first 
launched late 2005 and specialised in early stage investments in various areas of 
biotechnology like agriculture, biopharmaceuticals, diagnostics and biofuels. MTDC will 
acquire a maximum of 30% equity stake for a period of up to 5 years to allow the 
investee company to retain majority control to manage their company later on. Maximum 
funding is limited to US$8 million per company and the entire fund is valued at US$150 
million (Biotechcorp, 2009a). Various biotechnology firms have been the fortunate 
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recipients, like the Malaysian Bio-Diagnostics Research Sdn Bhd (MBDR) which will be 
covered in case studies later on in the paper.
The Commercialisation Research and Development Fund (CRDF) is a grant established 
towards assisting commercialisation efforts of local R&D activities. This grant provides 
partial grants to R&D projects that fulfil several criteria. Firstly, SMEs that conduct their 
own R&D in Malaysia can gain assistance from this grant to commercialise their 
discoveries. Secondly, biotechnology companies interested to undertake feasibility 
studies on public sector research institutes R&D results can gain assistance from this 
grant. Thirdly, commercial spin-off companies and subsidiaries affiliated with public 
sector research institutes and universities can get access to funding. Lastly public sector 
institutes that desire to commercialise their discoveries can apply for this fund to finance 
their new start-ups.   The maximum amount of funding is capped at RM$4 million or 
70% of the project cost. The funding also aims to increase leverages on science, 
technology and innovation for national development (BIOTEK, 2009b).
The Technology Acquisition Fund is a grant established to manage acquisitions of 
strategic and relevant technologies by the Malaysian Industrial Sector. The private sector 
is also provided partial funding to acquire new technologies and to improve their current 
technology and production processes. Local Malaysian companies intending to acquire 
foreign technologies need to incorporate the new capabilities into their existing systems 
immediately in order to qualify for the grant. Failure to do so will prevent them from 
receiving assistance from the grant. Acquisitions of foreign technologies cover these 
following aspects: technology know-how, patent rights, prototypes, design licensing and 
outright purchase of technology (BIOTEK, 2009b). Funding from this grant also covers 
eligible women entrepreneurs and given the additional option of acquiring equipment and 
machinery. 
Apart from BiotechCorp and MTDC’s commercialisation grants and private equity funds, 
biotechnology companies and entrepreneurs may secure funding for projects and start-ups 
through other government companies and agencies. 
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The list is as follow:
 Malaysian Debt Ventures (MDV)
 Bank Perusahaan Kecil & Sederhana Malaysia Berhad (SME Bank)
 Ministry of Science, Technology and Innovation (MOSTI)
MDV, incorporated on April 23rd 2002 is a wholly-owned subsidiary of the Ministry of 
Finance. MDV’s starting role was to manage financing and development of the 
Information and Communications Technology (ICT) industry and other high-growth 
sectors in Malaysia. This fund has an equity size of RM$1.6 billion or US$420 million, 
which is sourced from the government of Japan through the Japan Bank for International 
Cooperation (JBIC) (MDV, 2009). Currently MDV is tasked with securing funding and 
becoming another funding source for the biotechnology sector and include the industry in 
its high-growth sector portfolio. Alternative sources of financing are crucial for 
knowledge-intensive and technology-intensive start-up enterprises as intangible collateral 
such as ideas and R&D discoveries are its principal assets (MDV, 2009). MDV will 
contribute to finance biotechnology companies in Malaysia on acquisitions of equipment 
and infrastructure, and contracts/ projects; up to RM$120 million each. Working capital 
is financed up to RM$50 million. The grant is currently estimated at RM$2.5 billion. 
SME Bank, incorporated on October 3rd 2005 is a government-linked financing and 
business development institute. The bank’s main role is to finance SMEs and support or 
improve their business sustainability through advisory services when necessary. A fund 
was established  to function as a business loan to eligible SMEs for an amount of up to 
RM$5 million per company with the purpose of funding working capital, licensing of 
technologies and fixed assets financing. The total fund size is valued at RM$15 million.
MOSTI, first established in 1973 and restructured in 2004 is the leading agency of 
Malaysia for science, technology and innovation. The ministry has six conditional grants 
to finance and assist the biotechnology industry. These grants are open for applications 
by individuals or companies and cover technological, scientific, innovation and various 
biotechnological processes involving agro-biotechnology, genomic and molecular and 
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pharmaceuticals (Biotechcorp, 2009a). Funding amounts differ from various grants but 
the common aim is to assist the commercialisation process and aid the individual or 
company. 
Malaysia Intellectual Property Competitiveness
“It cannot be denied that intellectual property has been identified as one of the nation’s 
most valuable assets. Intellectual property rights play a significant role in the growth of 
supporting industries in particular, the small and medium enterprises”.
Datuk Hj. Mohd. Shafie Bin Hj. Apdal
Minister of Domestic Trade & Consumer Affairs
Foreword by Intellectual Property Corporation of 
Malaysia Annual Report 2007
Intellectual Property Corporation of Malaysia (MyIPO), established since 1983, is a 
government agency primarily responsible of enforcing intellectual property rights in 
Malaysia. This agency provides advisory services on intellectual property (IP) to 
individuals and companies, conduct training programs and initiatives to increase current 
numbers of IP managers; and provide statistical data on IP programs and information.
Intellectual property protection in Malaysia covers patents, trademarks, industrial 
designs, copyright, geographical indications and layout designs of integrated circuits 
(MIDA, 2009). Malaysia is also part of the World Intellectual Property Organisation 
(WIPO) and signatory to the Paris and Berne Convention which governs intellectual 
property rights. Patents in Malaysia are governed by legislation and an invention is 
patentable if it is a new process, or inventive step and applicable for industrial usage. The 
Patents Act in Malaysia follows TRIPS (Trade Related Aspects of Intellectual Property 
Rights) and awards a compulsory protection period of 20 years from date of application. 
The patent owner also has the right to assign, transmit and include a licensed contract. 
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The benefits of having a patent are to assist in company marketing purposes, rights of 
revenue source over the invention, bargaining chip to raise funds through venture 
capitalists or stock exchanges and creating a defensive market niche through temporary 
monopolistic rights. A quote by a CEO of a Malaysian biotechnology company:  “A quick 
look at Fortune’s Global 500 Rankings shows the dominance of American multinational 
companies comprising of 153 followed by Japanese companies at 64. Japan is a patent-
hungry nation as are the many European nations that figure strongly on the list. Looking 
at the Malaysian scenario…patents must spur national competitiveness that will make 
Malaysia into a developed nation”.
Datuk Dr Rajen M
CEO, Holista Biotech Sdn Bhd
There has been an annual increase in the applications for patents, trade marks and 
industrial designs. Malaysia also consistently ranked among the top-ten list of countries 
with the most number of patents’ application received, increasing from 206 to 3420 
approved patents from the year 2000 to 2007 (MyIPO, 2007). 
Despite Malaysia’s developing biotechnology industry, current progress has shown 
positive results. Furthermore there will be opportunities for Malaysia to increase to 
world-class levels as their biotechnology industry develops further. 
Malaysia has compiled statistics from 1986 – 2008 in the table shown in Table 2. There is 
a drop in patent applications in 2008. MyIPO Director General’s comment is as follows –
“Though the number of patents in 2007 increased 4%, the number of applications 
dropped 50.6% in 2008 after Malaysia joined the Patent Cooperation Treaty (PCT). The 
PCT system allows applicants to file their respective applications through Bureau of 
WIPO in Geneva instead of the respective country’s IP office”.
45
Application and Registration of Patent and Utility Innovations from 1986 to 2008
Year Application Received Registration
Malaysia Foreign Total Malaysia Foreign Total
1986-1998 1,805 41,014 42,819 286 10,380 10,666
1999 218 5,621 5,842 39 682 721
2000 206 6,021 6,227 24 381 405
2001 271 5,663 5,934 18 1,452 1,470
2002 322 4,615 4,937 32 1,460 1,492
2003 376 4,686 5,062 31 1,547 1,578
2004 522 4,920 5,442 24 2,323 2,347
2005 522 5,764 6,286 37 2,471 2,508
2006 531 4,269 4,800 187 6,562 6,749
2007 670 1,702 2,372 338 6,645 6,983
2008 864 4,539 5,403 198 2,044 2,242
Total 6,307 88,814 95,124 1,214 35,947 37,161
Patent and Utility Innovations Registration only start from 1988
Table 2: Application and Registration of Patents
(MyIPO, 2009)
Malaysia Patent Based on Field of Technology From year 2000 to 2008
SECTION 2000 2001 2002 2003 2004 2005 2006 2007 2008 TOTAL
A 61 155 206 224 325 333 948 1,179 423 3,711
B 59 233 236 242 377 452 1,155 1,213 421 4,258
C 110 288 334 396 625 600 1,275 1,748 451 5,662
D 8 18 19 28 25 30 101 109 33 360
E 19 44 42 38 50 82 197 221 98 761
F 42 102 104 119 132 164 448 407 159 1,625
G 36 231 228 190 321 316 1,042 883 293 3,449
H 70 399 323 341 492 531 1,583 1,223 364 5,218
TOTAL 405 1,470 1,492 1,578 2,347 2,508 6,749 6,983 2,242 25,044
Section A: Human Necessities
Section B: Performing Operations; Transporting
Section C: Chemistry; Metallurgy
Section D: Textiles; Paper
Section E: Fixed Constructions
Section F:
Mechanical Engineering; Lighting; Heating; 
Weapons
Section G: Physics
Section H: Electricity
Table 3: Patents Based on Field of Technologies
(MyIPO, 2009)
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Biotech Cluster strategies in Malaysia
Bionexus Network 
Initiated by Malaysian Prime Minister, Abdullah Badawai on 7th September 2006, the 
BioNexus network was started to aid and assist Malaysian and international 
biotechnology companies (Biotechcorp, 2008). The vision of the BioNexus Network is a 
creative cluster of biotechnology companies and organisations that can cooperate; enable 
transfers of technologies and develop new products. Universities and research institutions 
like centres of excellence play a major role in this cluster through the promotion and 
support of research and development in the biotechnology areas. To date there are three 
established centres of excellence throughout Malaysia, the Institute of Agricultural 
Biotechnology, the Malaysian Genome Institute and the National Pharmaceutical and 
Nutraceutical Institute. These are government linked and funded institutions; and are 
tasked to provide extensive research support through cooperative research programs with 
other research and development departments of biotechnology companies.
The Bionexus network is an exclusive cluster of biotechnology companies that has been 
targeted by BiotechCorp as industry leaders of their field and with internationalisation 
potential. These companies are supported by a variety of organisations like universities 
and research institutions throughout Malaysia. According to a press release by 
BiotechCorp, the number of Bionexus companies stands at 56 as of 31st March 2008 with 
total investments total US$383.6 million and R&D expenditure US$17.0 million. There is 
a set of Bills of Guarantees (BOG) that entitles Bionexus companies to several privileges 
like assistance for international accreditations and standards, access to supportive 
information network linking research institutes and assistance from BiotechCorp.  
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Centres of Excellence are government research institutes with the aim of undertaking 
world-class research and providing research facilities to biotechnology companies. There 
are at least three such institutes at this current point in time. 
They are:  Institute of Agricultural Biotechnology (ABI)
    Malaysian Genome institute (GENOMalaysia)
     National Pharmaceutical & Nutraceutical Institute (IPHARM)
ABI, founded on June 6th 2006, undertakes R&D and assists in project commercialisation 
related to agro-biotechnology. ABI relies on strategic links established with domestic and 
foreign universities, research institutes and other biotechnology firms (BIOTEK, 2009b).
GENOMalaysia is a network-based, not-for-profit organisation involved in R&D on 
tropical bioresources. The R&D projects range from genome sequencing, comparative 
and functional genomics and structural biology. An official forum/platform for gene 
discovery was established for the research and biotechnology business community to 
allow access to facilities in the institute and assist in difficulties faced. This is a result of a 
Memorandum of Understanding (MOU) between GENOMalaysia and the Department of 
Genetics, Stanford University (GENO, 2009). A new initiative to emerge was The 
National Biotechnology and Bioinformatics Network (NBBnet – Malaysia). It is a 
network of resources and infrastructure available for the Malaysian biological research 
community to learn and share within. Other functional roles of this network is to provide 
results of R&D processes, conduct research and training, maintain databases and online-
sharing with other related industries.
IPHARM is a research institute that conducts R&D on new drug discoveries and 
development. It has strategic links with other global research institutes to add onto its 
current capabilities. Development and commercialisation of new pharmaceuticals and 
nutraceuticals are one of the long-term goals of the institute (IPHARM, 2009). Short 
courses are available for interested scientists and academics wanting to improve their 
knowledge of current or newly-discovered processes.
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Triple Helix
The Triple Helix is an online initiative by BiotechCorp to enhance the biotechnology 
industry in Malaysia. Launched by Malaysia’s Prime Minister YAB Dato’ Seri Abdullah 
bin Haji Badawai during BioMalaysia 2008, the main aim of this program is to encourage 
cooperation between researchers, biotechnology companies and the government. The 
portal contains information on current projects and products developed by researchers 
and aims to achieve commercialisation through partnerships with Bionexus companies or 
government institutes. Access and information on services, equipment and facilities 
offered by research institutes, technology parks and affiliated universities are available 
through the portal. Bionexus companies are entitled to enquire to share research facilities 
and engage in R&D. 
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Methodology
Overview
This study focuses on investigating key priorities and capabilities for building a globally 
competitive and commercially-viable biotechnology industry and sector. Malaysia was 
chosen as it is an emerging player in the global and Asian biotechnology industry. As 
seen earlier, the Malaysian government and various governmental departments have 
identified the development and growth of a fledgling biotechnology and bioeconomy as a 
national priority to wealth creation and social well-being for all Malaysians in the 
country. 
In order to gather intimate knowledge of the Malaysian biotechnology industry, sampling 
was focused on companies and industry experts in the Bionexus network. Collaboration 
Literature Review
Research Question
Research & 
Procedure
Conclusion
 Defining core capabilities for building a sustainable 
bioeconomy
 Developing concepts for biotechnology clusters
 Do initial factor endowments affect the trajectory of a biotechnology 
industry?
 How should Malaysia prioritise, mobilise and coordinate scarce 
resources to build a sustainable bioeconomy?
Multiple Case-Studies
Confidential Personal Interviews
Survey/Questionnaire
 Leverage on existing advantages in agricultures, food and biofuels to 
build leadership position in respective biotechnology sectors
 The gap between desired and current capabilities provide a framework 
of improvement which the government has a central role of 
coordinating, resourcing and accelerating growth and resources of the 
nascent Malaysia bioeconomy
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was done with Biotech Corporation Sdn Bhd of Malaysia in order to gain access to the 
companies and encourage increased participation of the survey in view of Biotech 
Corporation’s endorsement of the study. Information on the Malaysian Bionexus 
database reflected a total of approximately 80 participants. Biotech Corporation sent each 
member company an email to notify and endorse the study. This was to encourage 
recipient-participation to make the study a success. A $10 donation was given to the local 
cancer society for every response received. 
Research objectives are: to explore growth patterns, industry platforms and networks, 
enabling factors that support entrepreneurial activity, innovation, productivity, 
sustainability and research development. Questions explored are: do initial factor 
endowments affect the trajectory of a biotechnology industry, and how should Malaysia 
prioritise, mobilise and coordinate resources to build a sustainable bioeconomy.
This study utilizes an online-survey, confidential interviews and case-studies. The survey 
was formulated with a triangulated design that involved interviews and five firms in a 
multiple-case studies approach (Jick, 1979; Sackett and Larson, 1990; Scandura and 
Williams, 2000; Yin, 1984). The five case studies consist of local companies in Malaysia 
operating in diverse biotechnology applications (e.g. diagnostics, biofuels, therapeutics, 
nutraceuticals, and devices) and have been compiled in order to capture a rich set of data 
relevant to the study.
The triangulation design synthesizes two research approaches: an inductive grounded 
theory analysis (Glaser and Strauss, 1967; Corbin and Strauss, 1990), and a hypothetico-
deductive scale development and testing methodology (Cook and Campbell, 1979; 
Popper, 1968; Stinchcombe, 1962; Salmon, 1971). The inductive approach utilizes 
theoretical sampling, collecting data from key informants, and coding, sorting and data 
comparison (Corbin and Strauss, 1990). The hypothetico-deductive approach utilizes 
interviews and a comprehensive literature review to identify specific antecedents to a 
viable and competitive bioeconomy. This is followed up by an online survey to validate 
these factors and generate an emergent grounded theory.
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A multiple-case study approach was done to enhance replication (Eisenhardt and 
Graebner, 2007; Yin, 1984). Five cases were chosen, designed and written for analysis 
and as independent experiments to record any emerging or current issues occurring in the 
Malaysian biotechnology industry. These Malaysian biotechnology firms operate in 
biofuels, nutraceuticals, biopharmaceuticals, diagnostics and devices; which allowed an 
adequate representation of the industry. Case study information was taken from company 
reports, publications, newspaper articles and scientific journals. Each case-study gave 
different viewpoints and a variety of potential variables necessary to build a bioeconomy. 
These were duly recorded and used for validation in interviews with Bionexus 
companies’ executives.
Raw data for the survey was collected in a rigorous and thorough process, employing 
theoretical sampling (Glaser and Strauss, 1967; Charmaz, 1983) with Bionexus industry 
executives, founders, entrepreneurs and scientists. These individuals were invited to 
provide data through personal but confidential face-to-face interviews. The participants 
were tasked to identify and evidence survey variables (Merton and Kendall, 1946). This 
was a crucial step in constructing and structuring the survey. 
For the first part of the interviews, open-ended questions were also asked to allow 
respondents’ freedom to express their views and opinions on their specific roles in 
biotechnology and bioeconomy, and their expertise on the various essential factors to 
build a sustainable world-class biotechnology hub. In the second-part of interviews, 
validation of raw data from earlier case-studies was crucial and needed to be tested with 
these industry experts and practitioners. They were asked to chose and rate a set of 
variables which they felt were ‘relevant’ when assessing the current state of their 
biotechnology industry, current and emerging issues; and essential factors to develop a 
competitive bioeconomy. 
Participants were asked to rate the items and variables identified in the literature research. 
This again gave validation and proof of relevance to the content and context on how the 
survey will be constructed. Therefore with the rated results, data collected from case 
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studies and interviews; the information was used to design and purpose-built the survey. 
These steps were necessary to ensure the survey itself would be understandable to 
practitioners and rigorous for academics to trust the derived data sets and allow 
replication in future studies. 
Based on the interviews and multiple case-studies, an online survey of 17 items was 
developed to validate findings related to the current state of the biotechnology industry, 
factors to innovation (Van de Ven et al., 1999) and perceived priorities and capabilities 
required to building a sustainable bioeconomy. There are 16 scaled items (importance, 
cross-validated, and ranked-order) which participants had to rank and answer. An open-
ended question was added at the end of the survey to capture a richer understanding of 
responses and identify possible omissions. The survey was posted online at 
surveymonkey.com as a third-party host in order to guarantee full or conceal anonymity 
of participants. 
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Introduction of methodologies 
Research Design
Triangulation
Triangulation is a common and well-known approach in mixed-methods research. The 
purpose is to obtain data on the same topic through different techniques, in order to 
increase understanding of the research problem (Creswell & Clark, 2007).  The aim of 
this methodology is to combine both quantitative and qualitative methods of data-
collection and reduce weaknesses in each individual method. Both data-collection 
methods are conducted concurrently, with each data-set separately analysed. The 
researcher can compare and contrast findings from both data-sets, combine both data-sets 
and write an overall integrated analysis and or validate one set of data from the other. 
Grounded-theory, attempts to analyse the data and identify key themes, patterns and 
categories from the data (Lancaster, 2003; Creswell & Clark, 2007). The benefit of 
grounded-theory is it offers explanations relevant to a particular set of circumstances and 
situations (Lancaster, 2003).  
For this study, a two-phase data collection research design is used. In the first phase, 
qualitative data-collection through multiple case-studies and a literature review will be 
undertaken to identify potential key concepts and variables. The findings will be 
validated with confidential face-to-face interviews with participants from the Bionexus 
network. The interviews will give a rich set of data that will provide insights into the 
necessary capabilities and priorities required to building a bioeconomy in Malaysia. After 
cross-validating data from the case-studies and literature review, new information derived 
from the interviews will be combined together with the cross-validated data to formulate 
a questionnaire. This questionnaire will survey the entire Bionexus network of companies 
to ascertain level of generalisability in results. 
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Case Studies
A case represents an existing phenomenon that is observed at a single point or over a 
period of time (Gerring, 2007)  and later portrayed through a study which simulates the 
situation that is put into context through a verbal representation of reality (Ellet, 2007). 
Thus a case-study can be referred to as an intensive study of a single case in order to 
understand a population sample. The inclusion of five cases in this paper was to form part 
of a multiple-case study, and is commonly referred to as cross-case since the assumption 
is that at a certain point it will not be feasible to study these cases intensively (Gerring, 
2007). The cases selected were representative of the biotechnology companies in 
Malaysia and of the Bionexus network. The number of case-studies is influenced by the 
research problem and the research objectives. As this paper is an exploratory study into 
Malaysia’s emerging biotechnology industry, it will be necessary to study at least one 
firm per biotech segment.
Company Type Biotech Sector
Industrial Oxygen Incorporated (IOI) Private Biofuels
Chemical Company of Malaysia (CCM) Private BioPharmaceuticals
BioFact Life Bionexus, Private Nutraceuticals
Malaysian Bio-Diagnostcs Research (MBDR) Bionexus, Private Diagnostics
StemLife Bionexus, Private Stem Cell Banking
Table 4: Case-studies Company Profiles
Typically a cross-case study aims to explain the phenomena superficially, whereas a case 
study will have in-depth analysis. Thus for each individual cases covered in this paper, 
initial analysis is conducted such as collecting data from the internet regarding the 
corporation, company websites, publications and newspapers. The data is recorded and 
paraphrased to explain the company’s activities, strategies and responsibilities. With 
these details of the company and further analysis is explained with knowledge from 
secondary sources like academic journals and corporate publications. 
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Preparing for a case study
This process goes through four stages: ‘drift’, ‘design’, ‘prediction’ and 
‘disconfirmation’. According to a figure provided by Bonoma in 1985 by (Ghauri & 
Gronhaug, 2005), these four stages are graphically depicted below.
Figure 4: Stages of Understanding in Case studies
In the initial stages, the researcher is in a ‘drift’ stage as he/she is trying to learn the area 
of research, varying concepts and terminologies used (Ghauri & Gronhaug, 2005). 
During this process, the researcher acquires basic knowledge about the subject and 
constructs themes surrounding the areas of interest. It is also during this stage that the 
researcher tends to restructure the research questions and knows where to find more data. 
In the second or ‘design’ stage, the researcher formulates a method to collect data to 
explain the research questions and establishing theoretical rigour in the case study. Later 
in the third or ‘prediction’ stage, with an advanced understanding of the case and 
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necessary factors, the researcher compiles and constructs the case to draw meaningful 
conclusions. Concepts and variables derived from this exercise will be validated by the 
interview-participants. This is also known as the final stage ‘disconfirmation’, to test the 
generalisability of results.
Interviews
Interviews are acknowledged as one of the most effective ways of data-collection in 
social science research (Lancaster, 2005; Ghauri & Gronhaug, 2005). Face-to-face 
interviews will be conducted to collect data, and complex issues can be explained and 
unclear issues clarified. Interviews are useful as the researcher is able to adapt the line of 
questioning to suit the circumstances and ensure the questions will be properly answered 
and explain meanings behind the concepts. In order to plan and conduct the interviews, 
data objectives and discussion topics were derived from the literature review and multiple 
case-studies. 
The first-half of interviews will be unstructured as the questions are open-ended to 
initiate conversation with the participant and gather insight on their views. The second-
half of interviews require participants to rate variables and concepts from the case-studies 
and literature reviews. This will be semi-structured as questions will be asked and 
validated against participants’ answers. Interview participants will be selected from 
Malaysia’s prestigious Bionexus network of biotechnology companies. Malaysia 
Biotechnology Corporation will send these companies an email and phone-call notifying 
them of this study and request their participation to make this study a success. These 
biotechnology companies are high-growth with internationalisation potential and are 
aided by the Malaysian government to spearhead growth of the bioeconomy. Interviews 
will be arranged directly through electronic-mail and phone-call communications with the 
researcher. This is to conceal their identities and maintain anonymity. The researcher will 
conduct the interviews at the participant’s office or otherwise planned.  
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Questionnaire
A questionnaire is a pre-formulated set of questions to which respondents record their 
answers within closely defined boundaries and alternatives (Cavana et al, 2001; Ghauri & 
Gronhaug, 2005). The questions for this survey were derived from key concepts and 
variables identified from the first-phase of qualitative data-collection. For this paper, 
closed questions were used in the survey to Bionexus participants. With closed questions, 
respondents would need to make a choice among a set of alternatives or choices 
provided. Respondents were also asked to rank or indicate their preference or opinions. 
Closed questions aid participants’ decision-making and researcher data-analysis. This 
limits the statistical methods and scope possible for analysis. The actual questionnaire is 
provided in the appendix at the end of this paper for review. 
Survey questions were kept extremely brief to avoid several things like phrasing words 
negatively or positively, biases in questions or leading questions; and to keep the survey 
as short as possible. An issue of awareness highlighted was the difference in language-
medium in Malaysia as Bahasa Melayu is the predominant language with English, a 
second language. Demographic data like years of experience, role in the company and 
principal residence were the kind of questions used to capture insights on the 
characteristics of respondents. The questionnaire also included an open-ended question 
which gave respondents the freedom to comment on any areas of interest and provide 
further insights to enrich the data collected. 
The questionnaire was planned for online distribution to Bionexus companies. Malaysia 
Biotechnology Corporation volunteered to send participant-companies an electronic-mail 
and a phone-call notifying them of this survey study and request for their participation.
Some benefits of online-distribution are; for example to provide fast access to computer-
literate respondents, rapid data-collection, visual aids may be used to aid partcipants’ 
response, participants feel anonymous and it is often the lowest-cost option (Cooper & 
Schindler, 2008). The questions in the survey were structured with ordinal and 
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categorical scales. Ordinal scales categorises variables to denote differences among 
various categories, and allows ranking of variables. However the ordinal scale does not 
provide an indication of magnitude in differences between each variable (Cavana et al, 
2001; Creswell & Clark, 2007).  The graphs will be analysed using descriptive statistics.
For validity and consistency of findings, the Cronbach’s Alpha will be used to 
statistically test the reliability of results from the top two priority capabilities identified 
by respondents. This test gives significance to the reliability of results and measurement 
instruments (Cavana et al, 2001).
Application for Human Ethics Commission (HEC) through Victoria University of 
Wellington was necessary to gain approval for the confidential interviews and 
anonymous questionnaire. This ensured a 3rd-party, i.e. Victoria University; was made 
aware of the researcher’s data-collection and that the survey would not cause harm or 
offend any potential participants. Gaining approval is essential as it gives respondents 
further assurance of their anonymity. The HEC forms were filled out by the researcher 
and discussed with the supervisor and school HEC representative. Once the forms were 
filled out appropriately, they were sent to the HEC Committee for formal approval of 
data-collection.
Research Methods
Data sources for the case-studies were through secondary data. The researcher started 
with a literature search on topics specific to each case and progressed onto other areas of 
interest. For example, if one of the biotechnology companies was involved in biofuels, 
then the research would be on the topic of biofuels, definition of biofuels, specifics and 
history of biofuels, global and local market growth and demand; and other underlying 
issues directly or indirectly affecting the company or industry. Therefore the list of 
secondary data sources includes books, journal articles, newspapers, government 
webpages and company websites. The advantage of using secondary data is the reduction 
in time and money spent to gather data. The researcher can commence research through 
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the internet or at the library. The researcher may draw conclusions or hypotheses rapidly 
once he/she validates the data sources and reliability of data. Through this exercise, the 
researcher managed to construct a background picture of each company and their 
respective business operations. Founding members and leading scientists were some of 
the people researched upon and highlighted to be responsible for the company’s growth 
and success. Further research was done to shed insight on their respective biotechnology 
sector and issues affecting their industries for example global events like an oil-crisis, 
Kyoto Protocol over carbon emissions, new international regulations restricting cross-
border stem-cell transfers and ethical dimensions on usage of regenerative medicine. 
Findings from the case studies were used to enrich questionnaire results. This was to 
provide an additional perspective as mentioned previously.  
Confidential interviews were conducted after contact with the researcher was made. The 
researcher arranged and conducted the interviews in Malaysia. Interviews were 
conducted in the participants’ office and at their convenience.  The researcher was 
present to explain or clarify any uncertainties regarding questions or confidentiality 
issues. The conducted interview pattern was listening, questioning, paraphrasing and 
probing in order to elicit answers and viewpoints by participants. Responses were written 
down and tape-recorded by the researcher for further analysis. Tape-recorded interviews 
do not contain any participant information in order to conceal anonymity.
The questionnaire was administered through an online website, 
www.surveymonkey.com. The web address containing the survey was provided to 
BiotechCorp for dissemination to Bionexus companies, along with a note requesting their 
participation in the survey. This survey was opened to all participants for a period of 
three months, from September to November 2008.  The measurement scales used in the 
survey were categorical and rating scales used were ordinal.
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Data Analysis
The raw data was downloaded from www.surveymonkey.com which hosted the online-
questionnaire. The website tabulates and presents all responses in the raw data-set 
according to the questions answered. For example, if each respondent has to select 7 out 
of 10 options and there are 34 respondents, the total count of responses should be 238. If 
there are lesser than that amount, there will be a ‘missing response’ section which will 
tabulate the amount. Missing and blank responses will be depicted in the graphs when 
necessary. The researcher is also aware that if a substantial amount of questions are left 
unanswered, there might be a problem with the questionnaire and the data-set is 
unsuitable for analysis. Since the survey was partially derived from interview responses, 
this may minimise the problem of editing and handling missing or blank responses.  The 
raw data-set was entered into Microsoft Excel for data analysis. Frequency distributions 
were tabulated to obtain information on demographic variables like occupation, work 
experience and principal residence. Descriptive statistics was undertaken for the rest of 
this paper and results were shown in bar-graphs through the Results section.
Limitations of methodology
Online questionnaires are a useful way to distribute results and gather responses. 
However it could also be generalised that computer-savvy respondents are more likely to 
participate than non computer-savvy participants. Utilising close-questions in the 
questionnaire aids meaningful analysis in some way but limits statistical testing. The time 
frame of this research is limited to 12 months and potential research-methods and 
researcher’s capabilities needed to be taken into account when choosing the appropriate 
methodologies for data-collection. Cross-case studies are practical for an informative 
insight into a large sample population; however deriving meaningful insights might be 
limited. Using only the Bionexus network of companies might give a narrow opinion or 
response since the unit under special focus is not perfectly representative of the 
population. However a perfect homogeneity across the sample and population is 
impossible to be assured (Gerring, 2007).
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Limitations of Study
Replicating social science research may provide a different answer from this study 
therefore a mixed-methods approach was adopted to increase credibility.
Acknowledgement is given on limitations of this study’s time-frame, researcher’s 
capabilities, sources of funding and support. The hope is for this study to provide grounds
for further and future research. Also it is acknowledged that there are too many variables 
to be considered and covered in a questionnaire that is designed to be brief and easy for 
respondents. 
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Case Studies
IOI Group Sdn Bhd
1. Company Background:
Industrial Oxygen Incorporated (IOI) Sdn Bhd is a Malaysian company formed on the 
31st of October, 1969 with the principal business in distribution of industrial gas. IOI 
converted to public status on the 29th of September, 1972 and was listed in the Kuala 
Lumpur Stock Exchange of Malaysia on 29th July, 1980 (IOI Group, 2008a). IOI Group 
started out in the real-estate market in Malaysia when it ventured into property 
development in 1984 and later delved into oil-palm plantations in 1985. Today, IOI is 
internationally renowned as a leading global integrated palm oil player with operations 
encompassing the entire oil-palm value chain from seedlings to plantations to crop-oil 
extraction and to diverse value-added manufacturing across more than 65 different 
countries. IOI also employs more than 30,000 workers of more than 23 different 
nationalities in 15 countries (IOI Group, 2008b)
1.2 Company Major Products/Technology:
IOI is currently involved in three different segments; Plantation, Resource-Based 
Manufacturing and Property. IOI view its product and service offerings as 
complementary in terms of internal usage for further value-add activities before reaching 
consumers and or being offered externally. The graph (refer to Figure 5) was provided by 
IOI to show how consumers could benefit from the eventual product or from a product 
anywhere in along its value-chain
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Figure 5: Business Processes and Valued Added Activities
(IOI, 2008a)
1.2.1 Plantation
Plantation comprises of two components, Agronomy and Estates & Mills. Agronomy is 
the science of soil management and the production of field crops (Dictionary, 2008). IOI 
relies and invests heavily on research and development in agronomy sciences with two 
centre of excellence on developing agronomy best practices and introduction of high 
yielding planting materials. This has allowed IOI to develop its own hybrid oil-palm seed 
that yields high oil content for harvesting to meet increasing global demands and is 
available for commercial sale (IOI Group, 2008c). IOI’s policies on Estates and Mills are 
on agri-sustainability and non-encroachment of natural forests in future expansions of 
plantation areas (IOI Group, 2008d). IOI currently has 12 oil-palm mills in Malaysia with 
a total milling capacity of 4, 100, 000 MT/Year. In recent years, the demand for oil-palm 
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in biofuels have increased which resulted in higher demand and high prices for crude 
palm; thus IOI has ventured into Indonesia to establish more plantations and mills. IOI 
was also awarded a license to build a biodiesel plant in Johor, Malaysia in 2007 at 
200,000 litres per annum.
1.2.2 Resource Based Manufacturing
This business arm is the downstream of IOI’s oil-palm value chain. The raw oil-palm can 
be processed and refined by IOI and channelled internally for further value-added 
processing or be sold to industrial consumers like other destination refineries for more 
specific refining (IOI Group, 2008e). IOI is also involved in oleo-chemicals and is 
currently Asia’s largest vegetable oil base manufacture. Oleo-chemicals are derived from 
renewable resources (vegetable oil) and are unlike petro-chemicals which have proven 
unsustainable in the long-term. IOI’s plants are ISO 9002 and 140001 certified to produce 
a very wide range of oleo-chemical products like fatty acids and esters, glycerine, fatty 
alcohols that have various industrial applications in food production, pharmaceutical, 
cosmetics and other industrial lubricants and products (IOI Group, 2008f). Lastly, 
speciality fats are a unique category of fats that have nutrition/ health supplement 
applications. IOI’s speciality fats businesses are operated under the IOI Loders Croklaan 
Group of companies which is the global business leader in this field (IOI Group, 2008g).
1.2.3 Property
The Property business arm consists of three segments: development, investment, and 
leisure and hospitality. IOI has around 162,000 square metres of net lettable areas in its 
investment portfolio comprising of commercial, office buildings and shoping malls in 
prime locations. These properties were developed by IOI’s property development wing 
and turned into long-term investment businesses for the company (IOI Group, 2008h). 
Leisure and hospitality is a natural extension of IOI’s property investment segment, 
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comprising of resort based golf courses, hotels and convention centres (IOI Group, 
2008i).
1.3 Founders:
The founder, Tan Sri Dato Lee Shin Cheng was first appointed to the Board on 21st July 
1981 (IOI Group, 2008j). He is an entrepreneur with experience in the plantation and 
property development industries and provides advisory guidance to a large number of 
industry groupings and organisations. Together with his brother, Lee Cheng Leang, 
executive director since 21st July 1981, who has considerable experience in the hardware, 
chemical and industrial gas industry (IOI Group, 2008k), IOI has thrived and grown into 
a dominant global player in its individual businesses and in Malaysia.
1.4 Corporate Social Responsibility
IOI’s approach to Corporate Social Responsibility (CSR) is to strike a sustainable balance 
between the conflicting demands of internal and external stakeholders in the company’s 
pursuit of profits and growth (IOI Group, 2008l). IOI promotes environmental 
sustainability through its plantation, downstream processing (i.e. oleo-chemicals and 
crude palm refining) and property development. IOI also undergoes a number of 
sustainability audits by regional and international bodies and seeks for all their plantation 
estates to be Roundtable on Sustainable Palm Oil (RSPO) – certified. With profits 
derived from its businesses, IOI uses it for social responsibility like education, 
community and employee benefits.
1.5 Case Study Reflection
As we can see from the short case study of IOI Group, their primary produce of palm oil 
is responsible for two of their business segments, Plantation and Resource Based 
Manufacturing. The interest in the renewable and biofuel industry has grown 
tremendously with environmental issues like global warming and reducing of carbon 
emissions and the need to find renewable energy resources to replace fossil fuels. This 
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has led to R&D for renewable fuels. The oil palm has emerged as the favoured biofuel
crop as it is aggressively cultivated by Asian nations who are able to produce at low-
costs. The IOI Group has to mitigate between Corporate Social Responsibility (CSR) for 
its palm oil operations and their wider business objectives. Environmental lobby groups 
have increasingly pressured their respective governments to monitor how palm-oil 
producers expand their plantations and acquire available lands. Sustainability audits are 
one of the ways of certifying the company’s CSR. IOI can purchase existing plantations 
instead of acquiring land for new plantations. IOI Group has shown diversification with 
sustainable short-term or other types of businesses supporting long-term palm oil 
operations.  Stakes in property development, rentals and investments are useful to sustain 
their biofuel business and distribute business risks amongst their different operations. 
67
Chemical Company of Malaysia (CCM) Berhad
1.1 Company Background
Chemical Company of Malaysia (CCM) Berhad established a presence in Malaysia since
1930 as a subsidiary of Imperial Chemicals Industries PLC (UK). In August, 1963, CCM 
became a fully Malaysian-owned corporation. CCM achieved significant corporate 
presence since it became publicly-listed in 1966 on the Malaysia Exchange (MYX) and is 
considered a ‘blue-chip’ company in the Malaysia Exchange with good returns to 
shareholders (CCM, 2008a).
1.2 Company Major Products/ Technology
CCM is presently involved in 4 types of businesses, from chemicals, fertilisers, 
pharmaceuticals and duopharma biotech. However CCM started out as an industrial and 
speciality chemicals company in Malaysia in the 1930s (CCM, 2008b) It has now grown 
in the South-East Asian region with full-fledged offices in Singapore and Indonesia. 
CCM is involved and deals primarily in the manufacturing and marketing of industrial 
and speciality chemicals. CCM currently represents over 50 world renowned principals in 
the region with a strong export business market presence in Malaysia, Singapore and 
Indonesia (CCM, 2008c). CCM started diversifying in September, 1966 to establish the 
fertiliser business and built a manufacturing plant (CCM, 2008d). In March, 1995, CCM 
first delved into the life sciences after acquiring a pharmaceutical company and thus 
established their pharmaceuticals division.
1.2.1 Chemicals
CCM Chemicals is the first business wing of CCM Bhd. This business wing has 
progressed from being an industrial and speciality chemicals plant to a manufacturing and
trading company; and is also currently involved in water engineering and services. CCM 
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Chemicals provides its industrial chemicals and acids to a diverse variety of industries 
like pharmaceuticals, glass and food.
1.2.2 Fertilisers
CCM Fertilisers manufactures compound fertilisers especially for commercial customers. 
Research and development for this business segment is heavily pursued to formulate the 
best fertilisers for both plantation and cash crops. This is essential as Malaysia is an 
agricultural country and CCM Fertilisers stand to benefit from a domestic market of 
farmers and corporations. The Malaysian government agricultural research institutions
also collaborate closely with CCM Fertilisers to produce fertilisers suitable for crops in 
Malaysia. 
1.2.3 Pharmaceuticals
CCM Pharmaceuticals has the reputation of being the largest domestic producer of 
generic drugs with over 280 products like antihistamines and antibiotics divided 
distinctively into ethical and over-the counter medication (CCM, 2008e). CCM 
Pharmaceuticals have close working relations with other laboratories in the United States 
of America and Canada which allows them to share new capabilities and enhance 
research and development progress. This multi-lateral network is an example of how 
CCM Pharmaceuticals keep abreast of global developments and ensure their products 
meet international standards. CCM Pharmaceuticals sells and distributes its wide range of 
products to customers like doctors, private/general practitioners, Chinese Medical Halls, 
pharmacies and hypermarkets. They export to more than 20 countries worldwide which 
includes Asia-Pacific and Asean and 20% of overall sales to Muslim countries.
1.2.4 DuoPharma Biotech
CCM acquired this latest business segment in 2005. The plant produces solutions for oral 
preparation, sterile injectables, haemodialysis and sterile irrigation. It has managed to 
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establish a niche market as a leading local manufacturer of sophisticated and specialised 
small volume injectable solutions in Malaysia (CCM, 2008f). DuoPharma works 
extremely closely with Pharmaceuticals as both segments require extensive and 
substantial investments either through research and development or the hiring and 
training of current and new personnel.
1.3 Corporate Governance
CCM follows and adopts the Malaysian code on corporate governance which sets out the 
principles and best practices on structures and processes used to direct and manage the 
company’s activities towards enhancing corporate accountability (refer to
http://www.sc.com.my/eng/html/cg/cg2007.pdf for more information on the Malaysian 
Corporate Governance). The objective is to realise long-term shareholder value and 
taking into account the interests of other stakeholders (CCM, 2008g) 
1.3.1 Board of Directors
The Board reviews and approves short-term budgets and long-term strategies for CCM. 
The Board also approves all acquisitions, major capital expenditure and disposal of 
investments. Internal control and risk management systems within the organisation are 
done with the Board and the Audit Committee. This allows the effective utilisation of 
CCM assets and reduces malpractices (CCM, 2008h). Appointments and re-election of 
the Board goes through a formal procedure. The existing Board can appoint new directors 
and re-elect current directors which is also subjected to shareholders’ vote of approval 
during the company’s Annual General Meetings.  
1.4 Case Study Reflection
As we can see from this short-case study, CCM started out as an industrial and speciality 
chemicals company in the 1930s and later diversified into the biopharmaceuticals from 
1995 onwards. This is an interesting prospect since the life sciences industry has been 
70
growing rapidly in the last decade and especially the biopharmaceutical sector. 
Biopharmaceuticals has been used to push the frontier of pharmaceutical products with 
the use of living cells. This has led to more discoveries and newer drugs to treat various 
ailments and diseases. As mentioned earlier, CCM Bhd is involved in the production of 
generic medicines. This is a useful advantage as Malaysia can target consumers that have 
lesser purchasing power in developing countries like Laos and Cambodia that are close in 
proximity. Another note, CCM Bhd has a focus on producing Halal medicines for export 
into Muslim countries and consumers. The global Halal market has increased in revenue 
and export potential has increased tremendously. Focusing on low-cost and halal 
medicines will be advantageous for CCM to establish a position in niche markets.
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BioFact Life Sdn Bhd
1.1 Company Background
BioFact Life Sdn Bhd, is a Malaysian biotechnology private limited company 
incorporated in February 2005 to cultivate cordyceps in a specially designed clean room 
environment. This new start-up was formed to align with the Malaysian government’s 
biotechnology policy, global biotechnology trends and is part of the BioNexus Network 
(Biofactlife, 2008a). BioFact Life is a seed-to-shelf approach company with extensive 
research and development. Seed-to-shelf approach is synonymous with farm-to-fork and 
seed-to-supper. This means that the paper trail of fully-documented traceability like 
audits and inspection is never interrupted from seed supplier all the way to the grower, 
storage, shipping and product distribution (CertID, 2008). It allows full accountability 
and total background information of how the product was grown and manufactured and 
sold to the consumer. The company produces cordyceps, manufactures and market the 
end-products in domestic and international markets. This has led the company to become 
one of the largest herbal healthcare product distributors in Malaysia, with an outstanding 
track record in offering OEM services (Biofactlife, 2008a).
1.2 Company Major Products/ Technologies
Cordyceps, well-known to traditional Chinese medicines and found primarily in China 
and Nepal is an expensive herb worth in excess of US$14,000 per kilogram at wholesale 
prices (Biofactlife, 2008b). BioFact Life’s method of cultivating cordyceps is unique as it 
is grown by regulating the temperature, humidity, oxygen, light and the acidity 
conditions. With such a controlled environment, the medicinal properties in the 
cordyceps are pharmacologically ten times more active than wild-grown ones. This has 
enabled them to be a pioneer in this field. With the farming of a single crop, the company 
has developed six products for sale. These products contain the main ingredient of 
cordyceps to provide health benefits in forms of capsules and powdered drinks. The 
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products are targeted and available to both genders and all age groups. There are also 
specific products that target men and possible sex-health issues; and other particular 
ailments like liver and respiratory allergies. The company consists of two major 
divisions; one being research and development and the other being standard 
manufacturing division. 
1.2.1 Research and Development
This business division is led by Chartered Scientist Dato Chang and is responsible for 
research into good cultivation practices of cordyceps and other herbs through the use of 
advanced biotechnology (Biofactlife, 2008a). Other responsibilities include technological 
innovation to improve the quality of product, new product development, product 
innovation, quality analysis and improvement (Biofactlife, 2008c). This division also has 
a Memorandum-Of-Understanding (MOU) with Usains Holding Sdn Bhd, a commercial 
arm of Universiti Sains Malaysia to collaborate in research and development studies for 
biotechnology.
1.2.2 Standard Manufacturing
This business division is responsible for the manufacturing of all types of herbals 
products by transforming raw materials into finished goods. Adopting a simple 
philosophy of continuous excellent product quality, products are manufactured according 
to the GMP standard of Good Manufacturing Practice with scientific and total quality 
management systems in place (Biofactlife, 2008d). To achieve this target, a quality 
department was set-up from the beginning to ensure total quality in all its manufacturing 
processes. The quality department includes QA (Quality Assurance), QC (Quality 
Control) and IPQC (In Process Quality Control). The QA team is responsible for 
developing a standard process and structured system for all production lines. The QC 
team performs inspections on the raw materials and finished products to ensure the 
products are within quality control limits. Lastly IPQC conducts sampling tests on 
products during the production process to ensure any material which does not meet the 
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required standards will not be processed in the next working stage (Biofactlife, 2008d). 
The quality department is also under the direct supervision of a professional management 
team to ensure total quality is not compromised and every process is strictly under control 
and complete with an audit system to ensure traceability.
1.3 Key Personnel
Dato Chang Eng Thuan, technical director of Biofactlife has thirty-seven years of 
experience in analytical chemistry. He holds a Bachelor of Science (Hons) in Chemistry 
from the University of Malaya (1969). He has attended advanced training programs in 
analytical chemistry and microbiology at the Laboratory of the Government Chemist, 
London; Mycotoxins analysis in the Tropical Product Institute and forensic science 
training at New Scotland Yard, London (Biofactlife, 2008e). He was also bestowed 
Chartered Scientist of the British Science Council and also has affiliations with the Royal 
Society of Chemistry, United Kingdom and Malaysian Institute of Chemistry. Besides his 
current tenure in BioFact Life, he is chairman of the Industrial Standards Committee on
Chemicals and Materials and a member of several statutory boards in Malaysia. He has 
published journal articles on toxicology and traditional Chinese medicines in both local 
and international publications and chemical conferences.
Dato Dr. Gan Ee Kiang holds the position as a pharmacology consultant in the company. 
He obtained his degree as a Doctor of Philosophy from the University of Western 
Australia in 1972. He has a strong background in academia from being a lecturer at the 
Universiti Sains Malaysia (USM) and later serving as Dean of School of Pharmaceutical 
Sciences at USM from 1979-1995. He was instrumental in setting up three new 
departments at USM; Drug Research Centre, National Poison Centre and National 
Doping Control Centre. He has published two books and over one hundred 
scientific/professional articles and is co-inventor of two patents (Biofactlife, 2008d). He 
was previously appointed and served as a temporary advisor to the World Health 
Organisation, member in the International Health Advisory Panel of the United States 
Pharmacopoeia Convention and at various international conferences. Other than his 
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current tenure at BioFact Life, he is active in community services and sits on the Board of 
Directors of several private limited companies and is also a consultant to venture capital 
companies (Biofactlife, 2008e).
1.4 Case Study Reflection
From this short case study, it is known that BioFact Life is a biotechnology company 
which cultivates and manufacture cordyceps into health-supplements for sale and export. 
However what is interesting is that the company has transformed the cultivation of a 
traditional Chinese herb using modern biotechnology to develop a line of nutraceuticals 
to address health issues. The idea of nutraceuticals originated in Japan in the 1980s when 
‘physiologically functional foods’ appeared on the market and were defined as having a 
positive health impact on the consumer apart from the basic nutritive value (Hardy, 
2000).
Three important lessons are drawn from this case; protecting their R&D innovation 
through IP, strategic alliances with partner-universities and commercialising a product 
with easy access to customer-markets. BioFact Life’s innovative process of cultivating 
cordyceps and patenting the entire process with Intellectual Property protection, 
demonstrates how a R&D discovery can be protected, commercialised and derived profits
from. The implementation of IP protection has proven useful and outlines how a 
company can protect their own R&D and IP. A strategic alliance with Universiti Sains 
Malaysia allows sharing of capabilities, networks and R&D knowledge to develop new 
products with cordyceps as the main ingredient. The relevance of this herb has 
importance in the Asia region and in traditional medicines. A major part of the 
nutraceutical and medicines industry in Asia carries a strong herbal and traditional 
medicine component. BioFact Life’s products infuses western technology with an Asian 
herb to derive products which can be targeted at nearby Asian markets
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Malaysian Bio-Diagnostics Research (MBDR) Sdn Bhd
1.1 Company Background
Malaysian Bio-Diagnostics Research Sdn Bhd (MBDR) was incorporated in 1994 and 
began operations in September 1995. It is 100% Malaysian-owned and was initially 
established as a company to commercialise research on the diagnosis of typhoid fever. 
MBDR has expanded into producing other various medical diagnostics products like 
pregnancy test kits, drugs of abuse and brugian filariasis (MBDR, 2008a). MBDR has 
also established strategic partnerships with various universities and research institutes to 
develop new medical diagnostic products for the detection of various diseases like 
tuberculosis, malaria, paratyphoid, HIV, Nipah Virus and Dengue (MBDR, 2008a). With 
cutting edge technology and extensive research, MBDR aims to position itself as global 
competitor in developing and marketing diagnostic tests. MBDR has managed to capture 
export markets in various countries like Indonesia, Philippines, Thailand, Vietnam, India, 
Pakistan and Australia. MBDR is also part of Malaysia’s BioNexus Network of
companies which allows the company access to a creative cluster of biotechnology 
companies and cooperates to develop new products and services. 
1.2 Company Major Products/ Technologies
By utilising technology platforms such as protein-based immunochromatograpy tests 
(ICT), polymerase chain reaction method (PCR) and enzyme linked immunosorbent 
assay method (ELISA); MBDR is a pioneer company in Malaysia to incorporate three 
technology platforms into its medical diagnostic products which serve the in-vitro
diagnostic (IVD) market (Biotechcorp, 2008a). MBDR’s products have a wide-variety of 
applications across all industries and can be seen in later analysis.
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1.2.1 Drugs of Abuse
These are rapid tests for drugs in detecting levels of opiate, commonly found in morphine 
and codeine; terahydrocannabinol (THC), found in marijuana; and other drugs like 
amphethamine and Methamphetamine (MBDR, 2008b). Detection of these drugs are 
done by urine testing which uses immunochromatography which is immersing a dip-stick 
into the urine and waiting for five minutes when a colour band will appear to show 
positive signs of drugs or two colour bands to show a negative presence of drugs MBDR 
has allocated a variety of applications for this sort of testing to pre-employment testing, 
scheduled drug-user testing, random testing or post-accident testing. This product by 
MBDR is rated as highly reliable, quick and easy to use and does not need any scientific 
surroundings and can be done at anytime and anywhere.
1.2.2 Filariasis
Lymphatic Filariasis is caused by three species of blood/ tissue worms. One hundred and 
twenty million people in 83 countries worldwide are infected and estimates of one billion 
people are at risk of acquiring infection of this disease. It is spread from an infected 
human to an uninfected human by mosquitoes. The danger of this infection is recurrent 
fever, lymphatic damage, renal damage and pulmonary disease (MBDR, 2008c). 
MBDR’s has a product test-kit which gives rapid results in 15 minutes and requires a
small amount of specimen like blood, serum or plasma. Like all its products, MBDR 
manufactured diagnostic kits are capable of being used in any type of environment.
1.2.3 Tuberculosis
Tuberculosis (TB) is an infection which commonly affects the lungs and can also affect 
the central nervous system like meningitis, lymphatic system and circulatory system. TB 
is one of the most deadly and common major infectious diseases today and roughly 
affects two billion people worldwide. TB increases at a steady annual rate of nine million 
new cases globally which results in two million deaths, mainly in developing countries 
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(MBDR, 2008d). MBDR uses a thermo-stabilised PCR mix which is ideal for private or 
hospital laboratories to conduct testing. Results are available within three hours and 
specimens of body fluids can range from sputum, gastric lavage, blood and others.
1.2.4 HIV/Aids
Acquired Immunodeficiency Syndrome (AIDS), is a chronic, life-threatening condition 
caused by the human immunodeficiency virus (HIV). It damages and destroys the cells in 
the immune system and interferes with the body’s ability to effectively fight viruses, 
bacteria and fungi. This makes an individual extremely susceptible to certain types of 
cancers and other opportunistic infections. This condition is usually spread through 
sexual contact with an infected partner and also through infected blood and shared 
needles contaminated with the virus. AIDS is currently a global epidemic with an 
estimated 38 million people living with HIV. This is an increasing problem in developing 
countries. MBDR’s diagnostic product uses an immunochromatographic test to detect 
antibodies of HIV in body fluids (MBDR, 2008e). By using a small volume of blood, 
serum or plasma, a laboratory worker needs to drip the sample into the receiver of the 
test-kit and results can be obtained in ten minutes. With such rapid diagnosis of HIV 
infections, MBDR has targeted this product at clinics, hospitals, private laboratories and 
for pre-marital screening.
1.2.5 Typhoid
Typhoid fever is an infectious disease caused by Salmonella. The disease lives in the 
faeces of human carriers and is transmitted through the consumption of food and water 
contaminated with typhoid. Symptoms vary from patients, ranging from headaches, 
diarrhoea, fever to delirium and shock. Typhoid is prevalent in the Asia Pacific region 
due to the tropical climate and in Africa and South America or places where poor 
sanitation and sewerage treatment systems are non-existent. The World Health 
Organisation estimates there are millions affected with typhoid annually and deaths 
average about 600,000 (MBDR, 2008f). MBDR’s has a diagnostic test-kit that utilises 
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only four drops of blood to obtain a serum for testing. The total test time is between 1-3 
hours to obtain a confirmed result and can be done outside a laboratory and no special 
equipment is needed.
1.3 Bio Science Team
MBDR’s research and development initiatives are conducted by its own in-house team of 
scientists which includes its chairman, Professor Dr Ong Kok Hai who has academic 
links to International Medical University of Malaysia as a Dean and Professor in 
Pathology. He received his Doctorate of Philosophy from Manchester University (IMU, 
2008) and is also actively involved in community service. MBDR also has a team of 
collaborating scientists from external institutions especially from Universiti Sains 
Malaysia (USM). Professor Asma Binti Ismail, deputy vice chancellor of Research and 
Innovation from USM received her formal education in the United States of America. 
She has a Doctorate of Philosophy from the University of Nevada specialising in the field 
of Cellular and Molecular Biology. She also serves on MBDR’s board of directors (USM, 
2008). Professor Asma is credited with the translation of scientific discovery of typhoid 
into 4 rapid diagnostic kits that has been successfully commercialised globally. She is 
currently actively involved in the World Health Organisation as a temporary advisor 
since 2002 in the Vaccine and Diarrhoeal Diseases and serves on several expert and 
national panels for the evaluation of National grants into research and development areas 
and biotechnology clusters.
1.4 Case Study Reflection
As we can see from this case study, MBDR is involved in the medical diagnostic sector 
of the biotechnology sector. MBDR’s products are manufactured with the idea of ease in 
usage with most products not requiring any special equipment or a laboratory 
environment. This allows medical practitioners or personnel to carry such test-kits into 
epidemic areas and to carry out initial analysis and diagnosis to ascertain the levels of 
infections. Furthermore the interesting part of medical diagnostics is that with improved 
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technologies, different medical equipments are becoming increasingly common and can 
be found in households. An interesting thing to note, MBDR has only resolved to 
manufacture and be involved in diagnostic kits that are applicable to diseases prevalent in 
countries near Malaysia like Typhoid and Tuberculosis. Though this can be viewed as 
peripheral participation in the global diagnostics market, it can also be judged as 
MBDR’s resource-based-view of overall-growth process. It means building and 
developing newer capabilities and products with easily-available resources. MBDR has 
focused on building capabilities and products in diseases that are prevalent in tropical 
environments. This is beneficial since R&D testing of their diagnostic products can be 
conducted onsite where MBDR is situated. 
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StemLife Malaysia Sdn Bhd
1.1 Company Background
StemLife Sdn Bhd is Malaysia’s first stem cell banking and therapeutics company. 
Established in 2001, StemLife was awarded the prestigious MSC status in 2002 which is 
formerly known as Multimedia Super Corridor, a government initiative to aid promising 
companies as they enter the knowledge and information technology era (StemLife, 
2008a). On 17 October 2006, the company went for listing on the Malaysia Exchange of 
Securities Dealing & Automated Quotation (MESDAQ). In 2007, StemLife was awarded 
BioNexus status which gives the company access to clusters of other promising 
biotechnology companies. StemLife has also been successfully involved in 19 
transplants, between both related and unrelated donor-patient cases for the treatment of 
leukaemia, heart disease, thalassaemia major and lymphoma (StemLife, 2008b). The 
company is also currently in collaboration with the Kuala Lumpur Sports Medicine 
Centre (KLSMC) to offer therapies for patients with joint cartilage injuries. StemLife is 
also a founding member of the Asia Pacific Cord Blood Bank Consortium (APCBBC) 
with active participation in R&D projects with over 150 leading hospitals and 450 
renowned specialists. This forum gives participants the opportunity to congregate and 
deliberate over current issues in stem cells like medical breakthroughs and industry or 
public perspectives in the Asia region. StemLife is ranked as one of the largest and 
reputable stem cell companies in South East Asia (StemLife, 2008a).
1.2 Company Major Products/ Technologies
StemLife provides cord blood banking services which stores umbilical cord blood for 
bone marrow transplants in paediatric leukaemia and adult stem cells for use in treatment 
of blood-related disorders, heart disease and sports and trauma injuries. Storage and 
cryopreservation of stem cells is an important criterion to maintain the quality. StemLife 
offers two different systems of storage; cryobags and cryovials. Clients get to choose 
their preferred method of storage. Umbilical Cord blood is harvested from the blood that 
81
remains in the cord and placenta after birth. StemLife offers their stem cell banking 
services to collect the cord blood immediately after delivery and cryogenically stores it 
for future use (StemLife, 2008c). Collections are done after normal or caesarean births 
and delivery procedures will not be affected. The collection occurs after the cord has 
been clamped and cut and the process takes less than 5 minutes. Parents who have made 
their decisions are able to enrol and take the collection kit to their hospital of choice. 
Shipping and handling of their baby’s cord blood will be taken care of by the company’s 
logistics representative (StemLife, 2008d). StemLife will process the incoming cord 
blood for storage, test for diseases and contamination and lastly, store it away in the bank 
(StemLife, 2008e). A preliminary report will be sent to confirm receiving of the cord 
blood and a complete report will be issued three to four weeks later. 
StemLife also provides stem cell banking for adults where the stem cells can be collected 
from the blood stream and stored under cryogenic conditions. Stems cells collected in this 
manner are termed as peripheral blood stem cells (StemLife, 2008f). Customers who 
wish to store their stem cells will have to come into the clinic to undergo a process called 
apheresis and the extraction process will begin. It will take roughly 4-5 hours and the 
patient is able to watch a movie, listen to their favourite songs or enjoy a foot reflexology 
massage (StemLife, 2008g). 
The storage of all stem cells is in StemLife’s own cryopreservation facility in central 
Kuala Lumpur, Malaysia. StemLife only uses the American Food & Drug 
Administration-approved storage systems to store the stem cells. With approved facilities, 
StemLife also participates in external quality assurance and accreditation programs to 
ensure quality assurance in their products, services and facilities to ease the minds of 
customers (StemLife, 2008a). In addition to the storing of stem cells, StemLife provides 
stem cell consultancy and therapeutic services in close cooperation with medical 
specialists to provide cost-efficient and personalised treatment. StemLife’s current stem 
cell therapy applications are in oncology, haematology, heart disease and diabetic foot
ulcers (StemLife, 2008a).
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1.3 Company Key Personnel
StemLife is led its own management team coupled with an overriding Board of Directors 
and an advisory panel of medical specialists. StemLife was started by three founders; 
Sharon Low, Christina Lim and Professor Dr Aw Tar Choon. 
Sharon Low, managing director since 2001, was a scientific researcher at a private 
research institute for the National University of Singapore and held a managing position 
for a South-East Asian internet company (StemLife, 2008h). She also holds an honours 
degree in Biochemistry from the University of Bristol, United Kingdom. 
Christina Lim, deputy managing director since 2002, was a director and general manager 
of a securities firm. Since her joining of StemLife, she has contributed tremendously with 
her experience of over 25 years in financial and management experience and oversees all 
operations and financial planning of the company (StemLife, 2008h).
Professor Dr Aw Tar Choon, Chief Medical Officer since 2001, was a group medical 
advisor to the Health Management International Group. He also co-founded two medical 
science companies in Thailand and Singapore. Dr Aw graduated from the University of 
Malaya Medical School and trained in internal medicine at the Singapore General 
Hospital and King College Hospital Medical School, United Kingdom (StemLife, 
2008h). Dr Aw has been the Chrief of Laboratory Medicine at the National University 
Hospital from 1988-2002 and the Vice-Dean of the National University of Singapore 
Medical School from 1994-2002. 
1.3.1 Company Advisory Panel
StemLife’s advisory panel consists of the international and medical board. Members are 
recruited and invited to join from a wide variety of institutions and they provide medical 
input on a voluntary basis which will assist in policy making and analysis. This will allow 
StemLife to grow as Malaysia’s top stem cell company and be a global player. The panel 
members will also assist in establishing relations between Malaysian and international 
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scientists in order to improve the company’s services and quality provided (StemLife, 
2008i). 
1.4 Case Study Reflection
In this case-study of StemLife, insight is shown on their business operating activities 
which involves cord blood banking and how the company has two panels of international 
advisors to grow the company in terms of new initiatives and provide itself with a ready 
pool of knowledge. With close mentoring provided by advisory panels, StemLife is able 
to keep abreast of new medical technologies and other outstanding issues surrounding the 
industry. The establishment of StemLife demonstrates the entrepreneurship of the three 
founders who capitalised on their scientific expertise and various connections to 
commercialise the company. StemLife’s participation and being a founding member of 
the Asia Pacific Cord Blood Bank Consortium provides the company a close insight into 
developments of stem cell banking in the Asia region. Additionally this forum provides a 
formal platform for StemLife to source potential collaborative partners in medical 
research and new technologies. Alternatively this forum can be viewed as a cluster of 
companies situated across geographical borders, with the potential of cross-border 
product-innovation and research, multi-layered networking and provide easier access to 
overseas markets and patients.
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Results
Survey Demographics
This study surveyed approximately 80 affiliated companies of Malaysia’s Bionexus 
network and received 34 responses (43% participation-rate) during the September –
November 2008 time period. Participants were allowed to select multiple roles in the 
biotech industry (i.e. scientific founder maybe a board member, academic researcher, or a 
service provider such as an attorney maybe also be an investor). In Figure 6, management 
(76%) and board member (32%) were the leading roles, with additional roles such as 
scientists (24%), service providers (9%), academics (6%), investors (6%) and 
government officials (6%). There were also several other types of roles found, such as the 
chief executive officer, entrepreneur and vice-presidents. The study also found that 41% 
of participants have more than 10 years of experience in the biotechnology industry (refer 
to Figure 7).
Figure 6: Roles of Participants
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Figure 7: Years of Experience
Priority Sectors and Competiveness
The next stage of the study was to find out the priorities among the biotechnology sector. 
This was assessed by force ranking each area in the industry – agriculture and foods, 
biofuels, environment, and medical devices. For this study (refer to Figure 8), 
participants indicated strongly that Malaysia needs to build on one of its traditional 
strengths, agriculture and food sector; with biofuels as a distant second priority.
Respondents noted that the Malaysian biotechnology industry is just starting to take flight 
and companies are venturing to establish their own research operations, therefore its 
imperative for the government to make sure these research ventures are well supported 
for the next three years of infancy and retain the intellectual property to enable further 
development of the value-chain. After identifying the priority sectors, participants were 
asked to assess Malaysia’s current global competitiveness in each biotech sector. The 
results mirrored the sector focus as agriculture and food was identified as the only 
area with overarching global competitiveness, with biofuels as a second but distant
area of competitiveness. Comments by a survey participant noted: “Healthcare 
biotechnology will definitely help Malaysia in the long run. But since palm oil is 
Years of Experience in the Biotech 
Sector
0-5 years
38%
5-10 years
21%
>10 years
41%
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abundantly available, focusing on biofuels will help Malaysia to achieve a leadership 
position in that sector. ”
An example of consideration is Industrial Oxygen Incorporated (IOI), Malaysia’s leading 
integrated palm-oil company. IOI has core capabilities in palm-oil production from 
seedlings to plantations, crop extraction; palm-oil and biofuel production. Also, IOI 
operates in more than 65 different countries and employing more than 30,000 employees. 
IOI has an annual production capacity of 4 million metric tonnes from 12 palm-oil mills 
in Malaysia, which produces oils for consumption and as well as biodiesel after being 
awarded a license in 2007 to build a biodiesel plant in Malaysia. The oil palm has the 
highest oil yield per unit area compared to other types of crops like rapeseed, soybean or 
sunflower. This has led to the oil palm being credited as the favoured crop for production. 
Furthermore the oil palm tree has a life-span of 25-30 years and with consistently high-
yields, this makes the oil palm a sustainable and renewable energy source. Secondly, the 
global production of biofuels increased from 4.8 billion to 16.0 billion gallons. 
Production levels should increase if petroleum prices prove too costly or unsustainable 
and non-oil producing countries switch to alternative fuel sources. The importance of 
biofuels should grow with improvement of current technology and a growing global 
sentiment supporting renewable-energy.
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Figure 8: Malaysian Bioeconomy – Priority Sectors vs. Competitiveness
Capabilities and Competiveness 
With the priority sectors established, the next critical issue was in identifying the 
capabilities required to enhance Malaysia’s relative global competitiveness. In Figure 9,
participants expressed strongly on two necessary critical capabilities – access to 
funding and talent. These two capabilities were ranked significantly higher than all other 
potential capabilities required to establish a sustainable bioeconomy and biotechnology 
industry in Malaysia. Coincidentally respondents rated Malaysia in these critical areas as 
‘average’ in terms of access to funding and talent. Respondents also noted that there was 
a need for smoother cooperation between government departments, irrespective federal or 
local. Suggestions included “There should be no conflict of interest and reduction of red-
tape between government-related agencies…we need cooperation between all parties and 
stakeholders to enhance the business environment and not to further complicate it”.
Respondents also pushed forth new learning initiatives to educate the various government 
departments about business management and critical elements to gain success in the 
biotech industry.
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Figure 9: Malaysian Bioeconomy – Priority Capabilities vs. Competitiveness
Access to funding was identified as the highest priority amongst the other critical 
capabilities necessary for enabling and accelerating the Malaysian bioeconomy.
Participants were asked to prioritize specific areas which could improve capability and 
increased competitiveness. For this study (refer to Figure 10), respondents expressed that 
both government (96%) and private stakeholders (93%) had an ‘important – very 
important’ role in building and accelerating funding for the Malaysian biotechnology 
industry. The government initiatives frequently highlighted were for less stringent 
government policies and regulations; research grants and financial incentives. 
Respondents called for equal access to markets, finance and assistance for all 
biotechnology companies without favour regardless of foreign/local status. Research in 
biotechnology is often long-term and developmental periods are risky, therefore there is a 
need to support current companies in midst of research and also encourage other 
companies to start their own research and development capabilities. Suggestions 
included: “A conducive environment for both personnel and company through tax cuts, 
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rebates or exemptions; foreign companies to be made eligible for government grants base 
on quality of work, similar to the current way which the Info-Communication Technology 
sector is supported; centralization of grants and financial assistance to avoid 
overlapping; championing agency or ministry to regulate, and promote Malaysian 
biotech industry in overseas and foreign markets; identify, build, support and fund 
potential clusters to world standards; control inflation to prevent labour costs from 
rising too fast;  Attracting foreign companies to start doing ‘world-class’ research in 
Malaysia is just winning half the battle, the other half lies in facilitating them to do good 
work”.
From a private sector perspective, many participants acknowledged that the Malaysian 
biotechnology industry is in its developmental stages and there is an urgent need of a 
supportive environment. Respondents mentioned that local bankers and commercial 
banks were too risk-adverse and had little knowledge of the biotechnology industry. This 
amounted to the lack of venture capital in view of these private investors being unable to 
make an informed decision or evaluation and this has hampered the growth of Malaysia’s 
biotechnology industry to move onto the next level. Respondents also cited – “a 
supportive environment for entrepreneurial activity is crucial and not just going through 
the motions; government policies and initiatives need to encourage growth rather than 
moderate growth at this stage; government venture companies should be consistent, 
transparent, accountable and corrupt free in their dealings and activities; friendly 
investment environment to enhance foreign investment.”  
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Figure 10: Access to Funding
A Cronbach’s Alpha test (refer to Figure 11) was conducted to ascertain the level of 
reliability in this finding. The closer the reliability coefficient gets to 1.0, the better. 
Therefore in general reliabilities less than 0.6 are considered to be poor and those over 
0.8 are considered very reliable. Therefore with a value of 0.916, the reliability of this 
result is extremely good.
Figure 11: Cronbach’s Alpha on Access to Funding
Reliability Statistics
Cronbach's Alpha
Cronbach's Alpha 
Based on 
Standardized Items N of Items
0.916 0.930 6
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An example of consideration is StemLife Sdn Bhd, Malaysia’s first stem cell banking and 
therapeutics company. Cord blood, was first identified as a source of human stem cells 
when the first cord blood transplant between siblings resulted in a successful outcome. 
StemLife started as a greenfield investment in 2001 by a technology entrepreneur and 
internationally trained clinical scientists. StemLife offers banking services for infant cord 
blood and adult stem cells; which are stored to treat paediatric leukaemia, blood-related 
disorders, heart-disease and trauma injuries. This is a unique form of service and 
StemLife has grown to be one of the largest and reputable stem cell companies in South 
East Asia. To date, StemLife is also involved in the Asia Pacific Cord Blood Bank 
Consortium as a founding member and R&D partner. Interest in cord blood and stem cell 
development has grown in the premise of regenerative medicine. Private cord blood 
banks have emerged since 2005 and achieved steady growth. These private banks charge 
a one-time fee to collect and an annual fee to store the blood in the bank. Funding these 
cord blood banks are capital-intensive and require large amounts of venture capital or 
seed funding. To highlight growth on this biotechnology segment, Viacell was acquired 
by PerkinElmer in 2007 for US$300 million. Viacell is well-known for developing new 
drug therapies from stem cells. Prior to acquisition, Viacell’s annual turnover was US$70 
million per annum and the stem-cell/cord-blood market is project to grow in the next few 
years.
Access to talent was seen as the second highest priority amongst industry 
participants. Respondents rated the undertaking of education, research and 
commercialization to build a world class biotechnology community as ‘important – very 
important’. Figure 12 results indicate that 100% of respondents rated ‘skilled graduates 
with world class training” as ‘important – most important’ factors. Skilled graduates with 
world-class training were rated at 90% as the most important. Respondents noted the 
need for a ‘specially-tailored’ education-program for local biotechnology graduates and 
Bionexus companies should be able to provide advice on the education through their 
recommendations and knowledge. Suggestions include “The government needs to utilize 
the skills available and encourage rolling out of training initiatives by Bionexus 
companies in their areas of expertise; inculcate biotechnology into the education system; 
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a need to groom local graduates to ensure they can meet the demands of top 
biotechnology companies who decide to establish themselves in Malaysia.
From a government perspective, immigration policies can be enhanced to attract foreign 
students to study biotechnology degrees in Malaysia. When these foreign students 
graduate, biotechnology firms in Malaysia can hire them immediately. These foreign 
students are a useful source of foreign talent that are already trained and require lesser 
time to settle in since they would have been in Malaysia for a while. 
Next in importance was a wide range of necessary factors to develop a talented 
workforce which included a pool of experienced entrepreneurs, top executives from 
biotechnology companies and experienced investors. Participants noted - “the focus 
needs to be building of specialized skills and experience in Malaysia, and developing the 
labour force on a senior level to compete on the global stage.”
Amongst all these different ideas, maintaining momentum was a key priority. “As 
scientists and business heads move to live in Malaysia, the government must induce these 
talented people to stay as long as possible to focus on their research or commercial work. 
If there is no continuity, then the industry will undoubtedly be affected...; there is a long 
way to go and there will always be a need to revise and strategise the initial plan from 
time to time...but stay focused on own strengths and capitalize on fundamental resources 
like local brains and talents. The biotech industry must be market-driven...and success 
for Malaysian companies should always be measured through sales and sustainability.”
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Figure 12: Access to Talent
A Cronbach’s Alpha test (refer to Figure 13) was conducted to ascertain the level of 
reliability in this finding. The closer the reliability coefficient gets to 1.0, the better. 
Therefore in general reliabilities less than 0.6 are considered to be poor and those over 
0.8 are considered very reliable. Therefore with a value of 0.946, the reliability of this 
result is extremely good.
Figure 13: Cronbach’s Alpha on Access to Talent
Reliability Statistics
Cronbach's Alpha
Cronbach's Alpha 
Based on 
Standardized Items N of Items
0.946 0.956 7
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A prominent theme mentioned which addresses both access to funding and talent is the 
need to establish international alliances and strategic partnerships between Malaysia
and other biotechnologically-advanced countries to cooperate on joint research and 
development. Comments by respondents were “Getting things done in Malaysia is 
difficult as most of what we are doing is being done for the first time...To move forward 
we should focus on smart partnerships;” “We have an insufficient talent pool and local 
talent is unable to do ‘cutting edge’ research in biotechnology at this point. Therefore, 
we need more foreign talent and R&D alliances with other firms to breach this current 
deficiency...this scenario might change in years to come when Malaysia has benefited 
from this interchange.”
To build on the importance of talent, the availability of support services and networks 
were deemed as a critical element to develop a sustainable bioeconomy with the 
characteristics of starting and managing intellectual-property-based ventures with 
specialist skills. These include having people like lawyers, accountants or contract 
research organizations. Therefore a sustainable bioeconomy needs a robust ecosystem of 
dyads or networks of relationships to achieve growth. For this study (refer to Figure 14), 
about 70% of respondents noted that the following were ‘important – very important’ for 
building a sustainable bioeconomy in Malaysia: investors (i.e. angel investors, venture 
capital), manufacturing capacity (i.e. research, process), government agencies, scientific 
advisory board members, IP (intellectual property) firms, CROs (Contract Research 
Organisation), accountants, investor/public relations.
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Figure 14: Malaysian Bioeconomy Ecosystem
Respondents indicated a preference to have close proximity with universities and 
research institutes. In Figure 15, 90% of respondents surveyed rated having a close 
proximity with universities and research institutes as “important – very important”. 
Respondents noted that academic staff in Malaysian universities should travel overseas 
for more research and conferences and encourage intellectual linkages.  Suggestions 
include “ We need to reduce red-tape and encourage academic staff of public universities 
to travel abroad to conduct scientific research and return to transfer skills to local 
graduates or head research departments; a platform or forum of scientists should be 
established to head a particular sector of Malaysia’s biotechnology in order to put 
research, regulations and commercialization into perspective.”.
From a government perspective, establishing a formal platform or forum of scientists to 
head a biotechnology sector, is a positive step. This encourages discourse between 
leading scientists and the government to work out new initiatives and future growth plans 
for Malaysia’s developing biotechnology sector. From a private sector perspective, if the 
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government establishes a formal platform or forum of scientists, this might encourage 
more venture capital investment into biotechnology companies. This view is based on the 
government playing a role in facilitating and partnering role with biotechnology 
companies in Malaysia. Venture capitalists will be ensured they have a unified voice 
through the newly-established forum to discuss any potential initiatives with the 
government. This is a way to protect their investments and decrease information 
asymmetry. Support for this viewpoint by respondents suggesting “We must have close 
and easy access to relevant target markets for the biotechnology venture…therefore we 
need access, communication and support…all these make venture creation sustainable”.
An example of consideration would be Biofact Life Sdn Bhd, a Malaysian Bionexus and 
nutraceutical private limited company incorporated in 2005. Biofact Life is a seed-to-
shelf approach company with extensive research and development. Seed-to-shelf means 
that the paper trail of fully-documented traceability like audits and inspection is traceable 
right from seed producer to production-distribution. Biofact Life produces cordyceps, a 
type of medicinal herb with advanced biotechnology and manufactures a variety of 
products with the herb as the main ingredient. Cordyceps is well-known to traditional 
Chinese medicines and found primarily in China and Nepal, worth in excess of $14,000 
at wholesale prices. Biofact Life utilises a unique method of farming the herb in a 
controlled environment that the medicinal properties of the herb are pharmacologically 
ten-times more active than wild-grown types. Biofact Life has a beneficial relationship 
through a Memorandum-Of-Understanding with Usians Holding Sdn Bhd, a commercial 
arm of Universiti Sains Malaysia to collaborate in research and development studies in 
biotechnology. This relationship seeks to improve on technological innovation to 
improve product quality, innovation, new product development, quality analysis and 
improvement. The Bionexus network consists of various institutes to support R&D in 
biotechnology.  There are three key centres of excellence and biotech clusters which 
consist of higher learning institutes like local universities, private research institutes and 
government-linked research boards.
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Figure 15: Proximity to Research centres
High quality education was chosen as the most important quality-of-life factor with 
quality healthcare next in importance. Results of Figure 16 show that 81% of 
respondents chose high-quality education as “important – very important”. Participants 
noted that foreign expats, scientists and workers need to be assured of their living 
standards by their employers and government prior to working in Malaysia. Respondents 
also suggested that personal tax cuts or exemptions be provided to key expats in the 
biotech sector to reward them for their pioneering efforts in starting up biotech 
companies. Other suggestions included were “Malaysia needs to attract top talent 
through scientists and business heads…one way is to benchmark current incentives by 
other countries and offer better terms; foreign expatriates might have spouses and 
families, therefore a liberalised immigration policy allowing the spouse to work whilst in 
Malaysia can be an enticement. 
Student enrolment-allocations at international schools can be awarded first preference to 
foreign expatriate children as a further added incentive to settle down and work in 
Malaysia. Biotechnology is a global business with heavy reliance on intellectual property 
and strategic links with foreign companies. Nevertheless firms will seek foreign talent to 
supplement existing talent.
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From a government standpoint, a liberalised immigration policy for foreign expatriates 
will be essential to increasing the current existing talent-pool and speeding growth of the 
Malaysian biotechnology. However a careful and incremental immigration policy should 
be implemented to attract useful foreign expatriates. They can be segmented into their 
varying scientific occupations, years of work experience, existing job-offers and or 
educational background. For example an application by a foreign fresh graduate, with an 
existing job offer should be expedited immediately by immigration as compared to a 
fresh graduate with similar qualifications but without an existing job offer. The 
proposition is favourable terms be awarded to workers, preferably with job offers from 
biotechnology firms and have suitable educational backgrounds. 
To develop a sustainable bioeconomy, foreign expatriates need to be attracted to stay in 
Malaysia for a considerable period. If they leave within the first or second year, 
biotechnology firms will have to seek new talent once again. Though with a liberal 
immigration policy, foreign expatriates might use Malaysia as an intermediary to gain 
valuable experience before trying to seek employment in other countries which might not 
have considered them initially. To note, a good way would be to retain an overall positive 
net-worth of foreign talent annually.
From a private sector perspective, a liberalised immigration policy will be beneficial as it 
will increase scope and ease for firms to hire foreign employees. Removing potential 
barriers will increase business potential and viability for firms to hire desired employees. 
Firms should also work with the relevant government departments to adjust or implement 
immigration and labour policies to suit current trends and improve on changes.
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Figure 16: Quality of Life Factors
Affordable commercial lab and office space was indicated as a priority amongst 
respondents. 90% of participants noted the need for affordable space as a means to 
decrease operating costs and increase viability (refer to Figure 17). Suggestions included 
“Biotechnology is risky business and help by the government to decrease costs will help 
businesses; more support services are necessary to renovate existing space for biotech 
lab needs; commercial space for laboratories need to be improved to suit international 
standards”.
From a government perspective, provisions for new commercial lab and office space was 
addressed and made available in the 9th Malaysia Plan which will put forth several billion 
Ringgit to develop and build creative clusters for biotechnology firms. Cluster locations 
are built around national research institutes in order to develop creativity and increase 
network linkages through bringing relevant biotechnology firms. For example, 
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biopharmaceuticals, nutraceuticals and medical diagnostic companies doing research on 
cancer would want to be situated closer to the National Institute for Cancer Research. 
From a private sector perspective, potential sites for clusters are deemed too far from 
commercial centres or towns. Thus several companies have approached local 
governments to secure favourable terms in order to establish businesses. Kuala Lumpur is 
the capital of Malaysia, but several other smaller cities and towns like Malaaca and Sabah 
have developed their own local bioeconomy through partnerships with private firms.
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Figure 17: Lab and Office Space
Pool of serial entrepreneurs was a high priority amongst respondents. 90% of 
participants rated the importance of serial entrepreneurs as “important – important”
(refer to Figure 18). This reflects the trend of having entrepreneurs to engage in start-ups 
and raise venture capital for companies. Respondents also mentioned the difficulty of 
securing funding either from local bankers and government departments. This difficulty 
is more so when the biotechnology company is foreign. Suggestions from the survey
were “make sourcing for funding easier for start-ups and foreign businesses through 
improving current capital markets; increase sources of funding through private and 
government stakeholders”.  
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From a government perspective, having a pool of serial entrepreneurs is positive 
especially when these people are part of a formal platform as suggested earlier. With a 
platform, potential issues and agendas can be addressed at national conferences and 
industry meetings to reach out to a wider audience and other stakeholders. Agendas 
pushed forth should be considered legitimate and representative of underlying 
stakeholders and members. National conferences and industry meetings were rated by 
75% of respondents as “important – very important”. 
From a private sector standpoint, biotechnology firms should stand to benefit with serial 
and possibly new entrepreneurs. Entrepreneurial education and research was rated by 
81% of respondents as “important – very important”. Suggestions by respondents include 
“entrepreneurial education is essential to advancements in the bioeconomy; we need 
more entrepreneurs and local and federal government need to introduce more incentives; 
risk-taking and venture capitalists are too few…respective government agencies 
responsible for venture creation need to understand how the private sector operates and 
works to motivate local entrepreneurs and attract foreign investors”.
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Figure 18: Entrepreneurial Environment
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Prompt review of regulatory fillings was seen as a high priority amongst 
participants. In Figure 19, respondents suggested that local requirements and regulations 
be improved or revamped to suit international standards for example Convention on 
International Trade in Endangered Species (CITES), World Health Organisation (WHO) 
and International Organization for Standardization (ISO) that might impede the biotech 
industry. Suggestions include “We need a common or international standard to work 
towards…as it establishes credibility for our local companies and a level playing field for 
foreign biotechnology companies; having two different standards will turn away 
international biotechnology companies which Malaysia is trying to attract; government 
agencies should work on the same platform, rather than differing standards”. 
Respondents highlighted the point that authorities for the various biotech areas need to be 
well-versed, ideally in the science itself as there are potential implications. Respondents 
mentioned “Authorities need to be well-versed and with a good background in the 
science itself in order to assess or review biotech-related policies and implement proper 
decisions; if the relevant authorities are unable to implement the right decisions, the 
industry will end up going around aimlessly”.
An example of consideration is Malaysian Bio-Diagnostics Research Sdn Bhd (MBDR), 
Malaysia’s leading diagnostics and Bionexus company. Incorporated in 1994 as a 
research-based biotechnology company, MBDR has since expanded into producing and 
exporting products. MBDR also has established strategic relationships with various 
overseas universities and research institutes to develop newer medical diagnostic 
products and grow its own intellectual knowledge-base. MBDR’s medical diagnostic 
products specialises in detecting diseases like malaria, dengue fever, Nipah Virus, 
typhoid, lymphatic filariasis and tuberculosis commonly found in tropical regions. 
MBDR has entered the diagnostics market in South-East Asian countries like Indonesia, 
Philippines, Thailand, Vietnam and others like India, Pakistan and Australia; and aspires 
to become a global competitor in medical diagnostics. As the healthcare biotechnology 
sector in Malaysia grows, access to patients for clinical trials will increase in importance. 
A view concerning such healthcare and medical diagnostic companies is that a large 
majority of drugs fail in the late and costly stages of human testing. Hence medical 
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diagnostics can play a major role in establishing initial results with human DNA through 
indicators to ascertain the likelihood of success prior to actual human trials.
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Figure 19: Access to patients and Markets
A regulatory environment that supports new venture creation was seen as a high
priority amongst respondents with a 100% response-rate indicating it as “important –
very important” factor (refer to Figure 20).  Respondents noted that the overall business 
environment in Malaysia was conservative and focus was on current core strengths like 
manufacturing and low cost/technology services. Respondent suggestions were “the 
government needs to revamp their marketing campaigns and include biotechnology as 
one of the new pillars of revenue creation for Malaysia in the 21st Century; public 
relation and marketing campaigns are useful but there must be adequate regulations in 
place to prevent malpractices and mis-use of funding; though the Malaysian bioeconomy 
is still developing, the government can derive lessons learnt from the experiences of other 
countries to introduce regulations to protect venture creation”.
From a government perspective, introducing regulations to moderate the business 
environment should assist Malaysia’s aspiration to achieve biotechnology success. At this 
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initial stage, the government can finance or ease regulations on certain biotechnology 
sectors like biofuels to capitalise on Malaysia’s natural advantage of growing palm fruit. 
Achieving success in biofuels will be useful as mentioned in earlier sections; since it puts 
Malaysia in a reputable position as a new-entrant in biotechnology and there are potential 
spill-over effects in other biotech sectors. 
From a private sector perspective, regulations on venture creation might stifle creativity 
and innovation especially when funding comes primarily from the government. Current 
venture capital funds are either solely government or mixed with private sector 
participation. Alternative sources of funding like public-listing, seeking angel investors or 
from local state governments might be useful. Respondents noted that success from
funding should be substantiated from business sustainability and long-term growth and 
investors should be aware that biotechnology is a long-term business. Respondents 
further mentioned the need for transparency in funding disbursements and for sound 
corporate governance in companies. This was to ensure accountability to various 
shareholders. 
An example of consideration is Chemical Company of Malaysia (CCM) Berhad, a 
subsidiary of Imperial Chemicals Industries PLC (UK) and now fully Malaysian-owned 
since August 1963. CCM has achieved significant corporate presence since 1966 when it 
first became public-listed on the Malaysia Exchange (MYX). CCM is currently 
considered a ‘blue-chip’ company on MYX with good returns to shareholders. CCM is a 
heavily-diversified biopharmaceutical company, presently involved in 4 types of 
businesses ranging from chemicals, fertilisers, pharmaceuticals and duopharma biotech. 
CCM started out as an industrial and speciality chemicals company in Malaysia and 
progressively diversified in 1966 to fertilisers and pharmaceuticals in 1995 respectively. 
CCM Pharmceuticals is Malaysia’s largest domestic producer of generic drugs with over 
280 products like antihistamines and antibiotics. CCM Pharmaceuticals has close 
working relationships with other pharmaceutical firms in the United States and Canada 
which allows sharing of new discoveries, capabilities and enhance R&D programs. With 
a multi-lateral network in place, CCM Pharmaceuticals is able to keep abreast of global 
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developments and for their exports to adhere to changing international standards. CCM 
adopts the Malaysian code on corporate governance which sets out the principles and best 
practices on structures and processes used to direct and manage the company’s assets and 
activities towards enhancing corporate accountability. CCM also has a board of directors 
that reviews and approves short-term budgets and long-term strategies and goals. An 
Annual General Meeting (AGM) is held yearly to appoint or re-elect current directors 
subject to shareholders’ vote of approval. The Malaysian code on corporate governance 
started as a private sector initiative and subsequent reviews later established a reform of 
standards on corporate governance on a macro and micro level. To date, the code is 
chaired by members from the public and private sector.  
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Figure 20: Favourable incentives and tax treatment
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Discussion
This paper serves to find out about the Malaysian biotechnology industry which is in its 
developmental stages; and survey perceptions and attitudes of industry participants 
regarding key attributes of developing a sustainable bioeconomy in Malaysia. Growth 
patterns, entrepreneurial activity, innovation, productivity, sustainability and funding 
were areas that formed the survey questions posed to respondents. Key questions 
explored were: Do initial factor endowments impact or affect the development trajectory 
of a biotechnology cluster in Malaysia? How should Malaysia prioritise, mobilise and 
coordinate scarce resources to build a competitive bioeconomy? 
A mixed-methods approach of data-collection was conducted to achieve a rich data-set. 
In-depth case studies, confidential personal interviews and an online-survey were the 
techniques used to gain insights into Malaysia’s developing biotechnology industry. Five 
case studies were undertaken and analysed, with each company representing a 
biotechnology sector; for example: biofuels, nutraceuticals, biopharmaceuticals and 
medical diagnostics. Biotechnology companies of the Bionexus network of Malaysia 
were surveyed with the assistance of Malaysia Biotechnology Corporation, a 
government-linked company established to spearhead the overall growth and 
development of biotechnology in Malaysia.
Confidential personal interviews were conducted on Bionexus industry participants and 
asked to provide their opinions on building a sustainable bioeconomy. For the first half of 
interviews, participants provided their opinions on open-ended questions. In the second 
half of interviews, participants were asked close-ended questions on concepts developed 
from the literature review and insights derived from earlier case-studies. Participants’ 
insights were duly recorded and their contribution led to developing an online survey.
From the survey, 34 responses were received out of 80 companies that were contacted to 
participate. In terms of demographics, 76% of respondents indicated they were part of 
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their company’s management panel or team with at least 41% having more than 10 years 
of experience working in the biotechnology industry.
Key findings are as follow:
1) Malaysia should leverage on existing advantages in agriculture and food and 
biofuels. Developing healthcare biotechnology capabilities will be extremely 
useful as long-term comparative advantage.
2) Access to Funding and Talent were deemed the most important variables to 
developing a sustainable bioeconomy. Existing government sources of 
funding should be made available to foreign biotechnology companies. 
Education programs should have inputs by Bionexus companies to ensure 
relevant course materials are taught.
3) Malaysia needs to maintain current growth rates by adding new initiatives and 
growth strategies into the future. Continuity is necessary and capitalise on 
fundamental resources.
4) Development of platforms or forum of scientists to lead respective 
biotechnology sectors with the government to enhance cooperation and 
leadership.
5) Dyads and networks of relationships were essential to building a robust 
bioeconomy. Investors, manufacturers and government agencies ranked 
highest.
Priority sectors and competitiveness was an important segment of the survey as the 
researcher wanted to establish if respondents’ viewpoints were similar to Malaysia’s 
ambitions. Malaysia has targeted the agriculture, healthcare and industrial biotechnology 
sectors as future growth areas. From the results, respondents indicated Malaysia should 
leverage on its existing advantage in agriculture and food and biofuels as the second 
most important priority. This response is typical of the economic theory of Resource-
Based-View where the competitive advantage of an entity lies in the application of 
valuable resources at the entity’s disposal (Wernerfelt, 1984). Therefore if the entity is 
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able to use these valuable resources and make it into a competitive advantage, this 
advantage should stay sustainable in the long-run. 
Respondents were asked to assess Malaysia’s current global competitiveness within each 
biotech sector. Agriculture and food were assessed to be “world-class” with biofuels 
seen as slightly “below-average” Respondents’ opinions were for Malaysia to focus on 
healthcare biotechnology in the long-term, and to develop biofuel capabilities through 
improving technologies to convert palm oil into fuel as a short-term achievement. 
Developing capabilities in biofuels in the short-term will be essential to Malaysia’s bid to 
establish a long-term leadership position as this will enhance the country’s reputation and 
credibility as a global producer and manufacturer of renewable fuels. 
Malaysia is naturally endowed with palm oil and establishing a early leadership position 
in biofuels will prove lucrative when fossil-fuel sources start diminishing. The attraction 
of biofuels should increase when fossil-fuel prices rise beyond record prices.
Several respondents suggested that Malaysia should increase developments in 
healthcare biotechnology to create comparative advantages similar to agriculture 
biotechnology. Estimates predict that healthcare will increase in prominence especially in 
developed nations as poor lifestyles, hectic work-life and increased health-awareness will 
spearhead demand. 
For capabilities and competitiveness, respondents were asked to indicate their opinions 
on what critical capabilities were necessary to establish a thriving bioeconomy. The 
results were Access to Funding was chosen as the most important; followed by 
Access to Talent, and both were also rated as average in competitiveness.
Respondents mentioned that Access to Funding was the most critical as biotechnology is 
a R&D-intensive industry and the entire value-chain process from research to product 
commercialisation normally takes a few years and requires extensive capital investment. 
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Initiatives suggested by respondents were for less stringent government policies and 
regulations; allow research grants to be based on ideas and financial incentives for start-
ups regardless of foreign or local status.  At this current stage, Malaysia has a wide 
variety of funding sources primarily through government agencies and several private 
equity firms. Introduction of new sources of funding might not have an immediate 
impact to ease funding difficulties; instead regulations should be relaxed with more 
emphasis on a ‘case-by-case’ scenario. At this early stage of development in a 
bioeconomy, having new sources of funding would require increased monitoring by the 
Ministry of Finance to ensure the new financial institutions are of excellent financial 
health. Moreover with the current economic crisis, there might be lesser sources of 
private funding. 
The establishment of Malaysia Biotechnology Corporation (BiotechCorp) and the 
involvement of numerous government institutions involved in the bioeconomy, shows 
that the Malaysian government seeks to play a more active role other than facilitating 
between local and foreign biotechnology companies. Having an active government 
presence establishes credibility and should attract foreign companies and investors to 
grow the Malaysian bioeconomy. However in most business industries, some form of 
self-regulation by the private sector is preferred as extensive legislation by the 
government is viewed as over-regulation and restrictive. In the end, respondents seem to 
advocate for government intervention with an institutional approach to building the 
bioeconomy but yet calls are made for the government to ease moderation and speed 
growth. 
Funding has emerged to be an important capability and respondents indicate their 
preference for benefits like exemption of corporate tax regardless of status (i.e.
pioneering company), easier foreign worker employment regulations and attracting more 
foreign companies into biotechnology clusters.
Respondents also mentioned that the government needs to introduce a supportive 
environment for entrepreneurial activity and government venture companies to be 
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consistent and transparent. Malaysia needs to review its current policies and 
regulations and benchmark with other nations who have successfully implemented 
policies to attract and support entrepreneurial activity. There is much to learn 
especially when America and Europe have had successful biotechnology industries for 
the past two decades. Benchmarking and closely mimicking what others have done might 
stem future innovation and creativity, but it will prove as a starting point and grow the 
bioeconomy.
Access to Talent was critical as respondents viewed it necessary to build a world-class 
biotechnology community. 90% of respondents indicated ‘skilled graduates with world 
class training’ as the most important factor towards building a reputable biotechnology 
community. The Ministry of Education has introduced numerous educational initiatives 
in schools from primary to university, in order to inculcate biotechnology into the 
education system.
Attracting international students will be an alternative to increasing the numbers of 
trained workers. Study scholarships and grants should be awarded to attract 
international student numbers. After training and educating these students, retention of 
these skilled workers can be through fulfilling a minimum bond-period or by convincing 
these workers to immigrate to Malaysia by awarding residency status. Several 
respondents also called for the government to ease recruitment of global talent into 
Malaysia to accelerate the biotech sector development. This is due to widespread 
recognition that a diverse range of experienced and networked investors, serial bio-
entrepreneurs and top executives from multinational companies are necessary to achieve 
competitiveness.
Respondents mentioned the need to maintain momentum as a key priority in ensuring 
continuous growth in Malaysia’s bioeconomy. Respondents remarked that the 
government needs to carry out promises advertised in the public relations campaigns and 
the need to revise long term plans and strategies. The Malaysian government developed 
the BioValley in 2001 as a creative cluster to attract foreign investors and companies. 
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This has yet to yield substantial results. For the short-term, BiotechCorp should 
continually procure more strategic alliances with foreign biotechnology companies. For 
the long-term, Malaysia should incrementally adjust their long-term plans to establish a 
thriving bioeconomy and with achievable short-term plans to support their objectives.
The availability of support services and networks that were deemed to develop a 
bioeconomy were investors, manufacturing, government agencies, scientific advisory 
board members, IP firms and contract research organisations (CRO). Previous research 
showed that with creation of a new biotechnology company, four new supporting 
companies are created. Furthermore with each new biotechnology job, fifteen other jobs 
in related and supporting industries are needed (Nbbnet, 2002). Developing a sustainable 
bioeconomy will require an extensive support system which Malaysia currently uses
government agencies. This will not be a long-term solution as current Bionexus firms 
have mentioned working with government agencies as either being too stringent or 
having differing standards. Utilising government firms as a starting point is practical, and 
this should filter off to new private start-ups. These new firms should be allowed to 
undertake or bid for sub-contracts or other minor roles in providing supporting services.    
Respondents noted the need to have a formal platform or forum of scientists to lead 
the biotechnology sector and establishing close proximity to universities and research 
institutes. Respondents want a private cum government sector movement to develop new 
initiatives and future growth plans. This will give biotechnology companies that are 
directly affected by any future plans to voice out their opinions. With the government 
playing a role in facilitating, supporting and partnering with biotechnology companies in 
Malaysia; and with an increase in discourse, venture capitalists will be encouraged to 
invest in Malaysia.
Biotechnology firms continually seek foreign talent as biotechnology is a global business 
which requires experienced employees, workers and scientists. Thus when companies 
hire foreign talent, social environment and welfare factors are parts of the equation which 
attract or discourage foreign talent. 81% of respondents rated high quality education as 
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“important – most important”.  Allocation of student enrolments at international 
schools in Malaysia can be preferentially offered to foreign expatriate children to 
entice foreign expatriates to settle and work in Malaysia.  Respondents also suggested 
a liberal immigration policy extended to foreign expatriates to increase the existing 
talent-pool in Malaysia. However a careful and incremental policy should be 
implemented to attract useful foreign expatriates. The proposition is favourable terms 
like personal income tax-rebates be offered to foreign expatriates with desirable 
skill-sets to commence work in Malaysia’s biotechnology focus areas. The viewpoint 
is to expedite immigration and work-permit applications for foreign talent with the 
necessary skill-sets to grow Malaysia’s bioeconomy. It does not mean that foreign talent 
without the right skill-sets are less desirable as Malaysia needs foreign talent. But ease of 
hiring foreign talents under targeted growth areas will create a faster inflow of talent that 
will positively impact and grow Malaysia’s bioeconomy.
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Recommendations
This is the list of recommendations for practitioners after careful consideration. This list 
is by no means exhaustive and is merely a guideline for future progress in developing 
Malaysia’s bioeconomy.
Short-term:
1) Malaysia should leverage on its existing advantage in agriculture and food and 
biofuels to establish leadership positions in the respective sectors.
2) Existing government sources of funding should be made increasingly available to 
all foreign biotechnology companies on a “case-by-case” basis. This is to reward 
deserving companies’ base on merit, rather than origin. 
3) Foreign expatriates with the desired skill-sets to commence work in Malaysia’s 
biotechnology focus areas should be awarded favourable terms.
Long-term:
1) More companies are needed to provide supporting services to biotechnology 
companies and new start-ups are a way to ensure dedicated support services are 
available.
2) Malaysia should increase developments in healthcare biotechnology to create 
long-term comparative advantages
3) Attracting international students to study biotechnology will be essential to 
training and developing skilled graduates who will be available for employment 
annually. 
Short-term objectives are essential as its benefits can be immediately realised within 1-2 
years of implementation as opposed to long-term objectives. Malaysia needs to review its 
long-term strategies and ensure its short-term objectives are able to guide progress 
towards the eventual goal. Benchmarking factors of success of other biotechnologically-
advanced countries are essential to establishing a foot-hold in success. Malaysia needs to 
focus on how resources are utilised towards success.
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Conclusion
Biotechnology is a global business with implications and social and economic benefits. 
This branch of science has evolved from a highly-specialised and regulated industry to an 
increasingly mainstream capability with diverse commercial applications. The researcher 
was guided by research objectives to assess Malaysia’s emerging biotechnology industry 
and the necessary capabilities to develop a sustainable bioeconomy. Biotechnology 
companies from Malaysia’s prestigious Bionexus network formed the survey sample 
population and all 80 were surveyed with 34 responses which gives a 43% response rate. 
Case studies were conducted as part of the data-collection through secondary sources to 
gain a richer insight into Bionexus and Malaysia’s biotechnology industry. From the case 
studies, insights were derived on factors of success like entrepreneurial founders, 
scientific advisory boards, venture capital funding, and strategic alliances with research 
partners and talented scientists. A triangulated design involving confidential interviews 
Literature Review
Research Question
Research & 
Procedure
Conclusion
 Defining core capabilities for building a sustainable 
bioeconomy
 Developing concepts for biotechnology clusters
 Do initial factor endowments affect the trajectory of a biotechnology 
industry?
 How should Malaysia prioritise, mobilise and coordinate scarce 
resources to build a sustainable bioeconomy?
Multiple Case-Studies
Confidential Personal Interviews
Survey/Questionnaire
 Leverage on existing advantages in agricultures, food and biofuels to 
build leadership position in respective biotechnology sectors
 The gap between desired and current capabilities provide a framework 
of improvement which the government has a central role of 
coordinating, resourcing and accelerating growth and resources of the 
nascent Malaysia bioeconomy
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and in-depth case studies, was later cross-validated with industry participants to construct
a questionnaire. This questionnaire was administered and distributed online to all 
companies in the Bionexus network.
In this study, the researcher explored the priorities and capabilities necessary to establish 
and develop a sustainable bioeconomy. The findings add to knowledge that in developing 
a biotechnology industry; funding, talent and government support are essential for 
creating an investor cum business environment. Firstly the respondents indicated initial 
factor endowments do affect the trajectory of a biotechnology industry which in this case 
as seen earlier, respondents urged Malaysia to establish a competitive advantage in 
biofuels since the country has ample supplies of palm oil. Malaysia has developed a 
thriving industry in traditional agriculture and food, thus the impetus is to adopt 
biotechnology to increase growth in this segment. This coincides with the Resource-
Based-View that an entity should build sustainable competitive advantage through 
available valuable resources. Respondents seem split or bimodal over the levels of 
government intervention and support. However results show that the government’s role is 
pivotal to establishing and growing a sustainable bioeconomy. Additional findings 
showed that access to funding and talent were the highest priority capabilities required 
for biotechnology companies to exploit sector priorities and commercial opportunities. 
Overall this study shows that the government has a critical role in building and 
coordinating infrastructure, building comparative advantages, accelerating technological 
and capital flows and sustaining growth levels. Malaysia is naturally endowed with vast 
amounts of natural resources and would prove fundamental to its bioeconomy. The 
questions of how these resources are applied are critical for its success.
The pitfall of this study is firstly, the questionnaire’s design consisted of close-questions 
which limited other forms of statistical analysis and limited the responses from 
participants. However this also meant the responses from participants were easier to 
analyse and derive assumptions from. Secondly, endorsement of this research by 
Malaysia Biotechnology Corporation might sway Bionexus participant responses, 
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however the results of this study indicates this risk to be minimal. Third, surveying 
biotechnology companies only from the Bionexus network might diminishe the value of 
the study as opinions of non-Bionexus biotechnology companies are yet to be considered. 
Fourth, the time-frame for this paper is only 12 months and extensive research methods 
would be unfeasible within this short time-frame. Fifth, there are many factors and 
variables that a survey is unable to totally capture in one study. Therefore it is 
acknowledged as a weakness in methodology.
Areas for future research include firstly, a mixed-methods approach of interviewing and 
surveying Malaysia biotechnology respondents needs to be undertaken once again and 
should include a representative sample of all biotechnology companies regardless of 
Bionexus status. This should give a richer and better set of data to increase 
generalisability of results. 
Secondly, this research results coincides with previous research outlining the importance 
of the government in growing a biotechnology industry due to their position to offer 
favourable terms and conditions or incentives. However if biotechnology firms are global 
by nature and tend to establish strategic alliances with other overseas firms, which allows 
them to cooperate cross-border in terms of manufacturing  and conducting R&D; will 
strategic alliances or a receptive government be more important? Will these two factors 
differ between small or large biotechnology companies?
Thirdly, how should Malaysia coordinate resources to ensure success? Should resources 
be distributed according to cluster, company potential or are there other factors to be 
considered? Efficient distribution of resources will be a crucial element to success. 
Biotechnology is an industry with high risks and long profit-waiting periods; therefore 
there is a need for caution and prudence in allocating and distributing resources to 
recipients.  
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Appendix
Questionnaire
Building Malaysian Biotech Capabilities and Competitiveness
1. Welcome!
Dear Friend of the Malaysian Biotech Industry:
My name is Melvyn Loh and I am currently undertaking a Master degree in Victoria 
University of Wellington. This study is a partnership effort between Victoria University 
of Wellington and Malaysia’s Biotech Corporation where I serve as a research partner 
and I am here to invite you to participate in this study of exploring how to build 
Malaysia’s biotechnology industry. Identifying areas of focus, required capabilities, 
competitiveness for the Malaysian biotech industry are critical to economic development 
and wealth creation. Please help us identify key priorities for building a world class 
biotech sector in Malaysia, by completing this brief and anonymous survey.
The private and public sectors in Malaysia have already mobilised to create business 
opportunities in areas such as human healthcare, diagnostics, medical devices, 
agriculture, biofuels, environment, and nutraceuticals. Recognising the growing 
importance and potential of biotechnology to broadly impact Malaysian economic 
development, several government initiatives and agencies are engaged in building 
capacity for accelerating sector growth. To build on early successes and momentum, we 
need to identify specific priorities, areas of focus, and opportunities for preferential 
investment in building a thriving bioeconomy to achieve top tier global competitiveness.
Victoria University of Wellington requires approval for research involving human 
participants through an ethics review process. This project has received the necessary 
approval to proceed. Please note that your information will be completely anonymous 
and shown only in aggregated form.  You don’t have to provide your name. A report of 
the findings will be made available for public download on Malaysia Biotechnology 
Corporation’s website. This survey should not take more than 10-12 minutes of your 
time. 
Thank you very much for your time in completing this survey which we hope will 
enhance Malaysia's biotechnology industry competitiveness. We appreciate your 
participation and leadership!
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Sincerely yours,
Melvyn Loh, Masters of Commerce & Administration Student, Victoria University
Mark J. Ahn, Professor & Chair, Science & Technology Entrepreneurship, Victoria 
University
_____________________________________________________
Please direct any questions about the survey to:
Melvyn Loh
Masters of Commerce & Administration Student
Faculty of Commerce & Administration
Victoria University of Wellington
Email: melvyn.loh@vuw.ac.nz
Mark J. Ahn, PhD
Professor and Chair, Science & Technology Entrepreneurship
Faculties of Commerce & Administration and Science
Victoria University of Wellington
E-mail: mark.ahn@vuw.ac.nz
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7. Thank you!
Thank you very much for your time in completing this survey which we hope will 
enhance biotech industry competitiveness in Malaysia. We appreciate your participation 
and leadership!
Please note that your information will be completely anonymous and shown only in 
aggregated form. For your participation we will send you a report of the combined results 
and findings.
Sincerely yours,
Melvyn Loh, Masters of Commerce & Administration Student, Victoria University
Mark J. Ahn, Professor & Chair, Science & Technology Entrepreneurship, Victoria 
University
_____________________________________________________
Please direct any questions about the survey to:
Melvyn Loh
Masters of Commerce & Administration Student
Faculty of Commerce & Administration
Victoria University of Wellington
Email: melvyn.loh@vuw.ac.nz
Mark J. Ahn, PhD
Professor and Chair, Science & Technology Entrepreneurship
Faculties of Commerce & Administration and Science
Victoria University of Wellington
Email: mark.ahn@vuw.ac.nz
